<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis - Martí‐Carvajal, AJ - 2015 | Cochrane Library</title> <meta content="Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis - Martí‐Carvajal, AJ - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010298.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis - Martí‐Carvajal, AJ - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010298.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010298.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis" name="citation_title"/> <meta content="Arturo J Martí‐Carvajal" name="citation_author"/> <meta content="Iberoamerican Cochrane Network" name="citation_author_institution"/> <meta content="arturo.marti.carvajal@gmail.com" name="citation_author_email"/> <meta content="Vidhu Anand" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Ivan Solà" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD010298.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/04/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010298.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010298.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010298.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Janus Kinase 1 [*antagonists &amp; inhibitors]; Janus Kinase 2 [*antagonists &amp; inhibitors]; Nitriles; Primary Myelofibrosis [*drug therapy, mortality]; Protein Kinase Inhibitors [*therapeutic use]; Pyrazoles [*therapeutic use]; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010298.pub2&amp;doi=10.1002/14651858.CD010298.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010298\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010298\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010298.pub2",title:"Janus kinase\\u20101 and Janus kinase\\u20102 inhibitors for treating myelofibrosis",firstPublishedDate:"Apr 10, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010298.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010298.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010298.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010298.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010298.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010298.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010298.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010298.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010298.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010298.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2231 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010298.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-sec-0117"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-sec-0030"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/appendices#CD010298-sec-0122"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/table_n/CD010298StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/table_n/CD010298StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/information#CD010298-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Arturo J Martí‐Carvajal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/information#CD010298-cr-0003">Vidhu Anand</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010298.pub2/information#CD010298-cr-0004">Ivan Solà</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/information/en#CD010298-sec-0143">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 April 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010298.pub2">https://doi.org/10.1002/14651858.CD010298.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010298-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010298-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010298-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010298-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010298-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010298-abs-0001" lang="en"> <section id="CD010298-sec-0001"> <h3 class="title" id="CD010298-sec-0001">Background</h3> <p>Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non‐hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative. Janus kinase inhibitors are a novel strategy to treat people with myelofibrosis. </p> </section> <section id="CD010298-sec-0002"> <h3 class="title" id="CD010298-sec-0002">Objectives</h3> <p>To determine the clinical benefits and harms of Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis secondary to hematological or non‐hematological conditions. </p> </section> <section id="CD010298-sec-0003"> <h3 class="title" id="CD010298-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library 2014, Issue 11), Ovid MEDLINE (from 1946 to 13 November 2014), EMBASE (from 1980 to 12 January 2013), and LILACS (from 1982 to 20 November 2014). We searched WHO International Clinical Trials Registry Platform and The metaRegister of Controlled Trials. We also searched for conference proceedings of the American Society of Hematology (from 2009 to October 2013), European Hematology Association (from 2009 to October 2013), American Society of Clinical Oncology (from 2009 to October 2013), and European Society of Medical Oncology (from 2009 to October 2013). We included searches in FDA, European Medicines Agency, and Epistemonikos. We handsearched the references of all identified included trials, and relevant review articles. We did not apply any language restrictions. Two review authors independently screened search results. </p> </section> <section id="CD010298-sec-0004"> <h3 class="title" id="CD010298-sec-0004">Selection criteria</h3> <p>We included randomized clinical trials comparing Janus kinase‐1 and Janus kinase‐2 inhibitors with placebo or other treatments. Both previously treated and treatment naive patients were included. </p> </section> <section id="CD010298-sec-0005"> <h3 class="title" id="CD010298-sec-0005">Data collection and analysis</h3> <p>We used the hazard ratio (HR) and 95% confidence interval (95% CI) for overall survival, progression‐free survival and leukemia‐free survival, risk ratio (RR) and 95% CI for reduction in spleen size and adverse events binary data, and standardized mean differences (SMD) and 95% CI for continuous data (health‐related quality of life). Two review authors independently extracted data and assessed the risk of bias of included trials. Primary outcomes were overall survival, progression‐free survival and adverse events. </p> </section> <section id="CD010298-sec-0006"> <h3 class="title" id="CD010298-sec-0006">Main results</h3> <p>We included two trials involving 528 participants, comparing ruxolitinib with placebo or best available therapy (BAT). As the two included trials had different comparators we did not pool the data. The confidence in the results estimates of these trials was low due to the bias in their design, and their limited sample sizes that resulted in imprecise results. </p> <p>There is low quality evidence for the effect of ruxolitinib on survival when compared with placebo at 51 weeks of follow‐up (HR 0.51, 95% CI 0.27 to 0.98) and compared with BAT at 48 weeks of follow‐up (HR 0.70, 95% CI 0.20 to 2.47). Similarly there was very low quality evidence for the effect of ruxolitinib on progression free survival compared with BAT (HR 0.81, 95% CI 0.47 to 1.39). </p> <p>There is low quality evidence for the effect of ruxolitinib in terms of quality of life. Compared with placebo, the drug achieved a greater proportion of patients with a significant reduction of symptom scores (RR 8.82, 95% CI 4.40 to 17.69), and treated patients with ruxolitinib obtained greater MFSAF scores at the end of follow‐up (MD ‐87.90, 95% CI ‐139.58 to ‐36.22). An additional trial showed significant differences in EORTC QLQ‐C30 scores when compared ruxolitinib with best available therapy (MD 7.60, 95% CI 0.35 to 14.85). </p> <p>The effect of ruxolitinib on reduction in the spleen size of participants compared with placebo or BAT was uncertain (versus placebo: RR 64.58, 95% CI 9.08 to 459.56, <i>low quality evidence</i> ; versus BAT: RR 41.78, 95% CI 2.61 to 669.75, <i>low quality evidence</i>). </p> <p>There is low quality evidence for the effect of the drug compared with placebo on anemia (RR 2.35, 95% CI 1.62 to 3.41), neutropenia (RR 3.57, 95% CI 1.02 to 12.55) and thrombocytopenia (RR 9.74, 95% CI 2.32 to 40.96). Ruxolitinib did not result in differences versus BAT in the risk of anemia (RR 1.35, 95% CI 0.91 to 1.99, <i>low quality evidence</i> ) or thrombocytopenia (RR 1.20; 95% CI 0.44 to 3.28, <i>low quality evidence</i>). The risk of non‐hematologic grade 3 or 4 adverse events (including fatigue, arthralgia, nausea, diarrhea, extremity pain and pyrexia) was similar when ruxolitinib was compared with placebo or BAT. The rate of neutropenia comparing ruxolitinib with standard medical treatment was not reported by the trial. </p> </section> <section id="CD010298-sec-0007"> <h3 class="title" id="CD010298-sec-0007">Authors' conclusions</h3> <p>Currently, there is insufficient evidence to allow any conclusions regarding the efficacy and safety of ruxolitinib for treating myelofibrosis. The findings of this Cochrane review should be interpreted with caution as they are based on trials sponsored by industry, and include a small number of patients. Unless powered randomized clinical trials provide strong evidence of a treatment effect, and the trade‐off between potential benefits and harms is established, clinicians should be cautious when administering ruxolitinib for treating patients with myelofibrosis. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010298-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010298-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010298-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010298-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010298-abs-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010298-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010298-abs-0003" lang="en"> <h3>Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis</h3> <p><b>Review question</b> </p> <p>We reviewed the effects of Janus kinase‐1 and Janus kinase‐2 inhibitors for treating people with myelofibrosis. </p> <p><b>Background</b> </p> <p>Myelofibrosis is a disorder of the bone marrow in which the bone marrow is replaced by fibrous tissue. The symptoms depend on the degree of anemia and enlargement of the spleen. This condition has a poor prognosis and generally its treatment is palliative. </p> <p>Ruxolitinib is a drug in the class of Janus kinase inhibitors that tries to block the enzyme that derives in the scar tissue. </p> <p><b>Study characteristics</b> </p> <p>We identified two clinical trials that included a limited number of patients comparing ruxolitinib to placebo or standard medical treatment. Both studies were published in 2012, and were conducted in the United States of America (USA) and the United Kingdom (UK). Drug companies sponsored both trials. </p> <p><b>Key results</b> </p> <p>Although the results of the studies only showed a moderate improvement of patients treated with ruxolitinib in terms of their quality of life and a reduction in their spleen size, we could not be sure whether these effects were reliable because of the limitations of the studies and the low number of people they recruited. We also could not be sure whether the drug has an effect on overall survival compared with a placebo, or when it was compared with an active treatment. The effect of ruxolitinib in terms of progression‐free survival was also uncertain. In addition, people treated with this drug showed higher rates of anemia, thrombocytopenia and neutropenia compared with patients treated with a placebo, but the rate of adverse effects was similar to those treated with a medical treatment. </p> <p><b>Quality of evidence</b> </p> <p>The confidence in the results of this review is very low. The studies have limitations in the way they were designed and executed. Moreover, the limited number of patients included in the studies led to imprecise results. Larger studies should provide more information about the effect of ruxolitinib. </p> <p>Researchers from Cochrane searched all available literature up to 13 November 2014.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010298-sec-0117" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010298-sec-0117"></div> <h3 class="title" id="CD010298-sec-0118">Implications for practice</h3> <section id="CD010298-sec-0118"> <p>Currently, there is insufficient evidence to allow any conclusions regarding the efficacy and safety of ruxolitinib for treating MF. The results for the efficacy and safety outcomes in this Cochrane Review come from two small trials. The findings need to be interpreted with caution as they are based on trials sponsored by pharmaceutical company, including small number of patients. Unless RCTs provide strong evidence of a treatment effect, and the trade off between potential benefits and harms is established clinicians should be cautious when recommending and administering ruxolitinib for treating patients with MF. </p> </section> <h3 class="title" id="CD010298-sec-0119">Implications for research</h3> <section id="CD010298-sec-0119"> <p>There is a need for powered RCTs which assess the effect of ruxolitinib in patients with MF. The potential trial should be based on patient‐centered outcomes, such as overall survival, progression‐free survival, quality of life measures, safety and esophogeal varices and splanchnic vein thromboses rather than spleen measure. Furthermore, the potential trial should have an adequate duration of follow‐up. It should be based on median overall survival for low risk, intermediate‐1 risk, intermediate‐2 risk, and high‐risk MF patients according to the International Working Group for Myelofibrosis Research and Treatment report (<a href="./references#CD010298-bbs2-0033" title="CervantesF , DupriezB , PereiraA , PassamontiF , ReillyJT , MorraE , et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood2009;113(13):2895‐901. [PUBMED: 18988864] ">Cervantes 2009</a>). Due to risk of myelosuppression there is need for more well‐conducted trials with risk‐stratification to study the independent risk‐benefit ratio in different risk‐groups. </p> <p>Potential trials should be conducted with appropriate blinding of outcome assessment for subjective end points (quality of life measures). They should be planned using Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) (<a href="./references#CD010298-bbs2-0035" title="ChanAW , TetzlaffJM , AltmanDG , DickersinK , MoherD . SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet2013;381(9861):91‐2. [PUBMED: 23305999] ">Chan 2013a</a>; <a href="./references#CD010298-bbs2-0036" title="ChanAW , TetzlaffJM , AltmanDG , LaupacisA , GøtzschePC , Krleža‐JerićK , et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine2013;158(3):200‐7. [PUBMED: 23295957] ">Chan 2013b</a>; <a href="./references#CD010298-bbs2-0037" title="ChanAW , TetzlaffJM , GøtzschePC , AltmanDG , MannH , BerlinJA , et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ2013;346:e7586. [PUBMED: 23303884] ">Chan 2013c</a>) and reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement for improving the quality of reporting of efficacy and of harms in clinical research (<a href="./references#CD010298-bbs2-0031" title="CalvertM , BlazebyJ , AltmanDG , RevickiDA , MoherD , BrundageMD . Reporting of patient‐reported outcomes in randomized trials: the CONSORT PRO extension. JAMA2013;309(8):814‐22. [PUBMED: 23443445] ">Calvert 2013</a>; <a href="./references#CD010298-bbs2-0076" title="IoannidisJP , EvansSJ , GøtzschePC , O'NeillRT , AltmanDG , SchulzK , et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine2004;141(10):781‐8. [PUBMED: 15545678] ">Ioannidis 2004</a>; <a href="./references#CD010298-bbs2-0098" title="MoherD , HopewellS , SchulzKF , MontoriV , GøtzschePC , DevereauxPJ , et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c869. [PUBMED: 20332511] ">Moher 2010</a>). The trials should be conducted according to the Patient‐Centered Outcomes Research Institute (PCORI) recommendations (<a href="./references#CD010298-bbs2-0027" title="BaschE , AronsonN , BergA , FlumD , GabrielS , GoodmanSN , et al. Methodological standards and patient‐centeredness in comparative effectiveness research: the PCORI perspective. JAMA2012;307(15):1636‐40. [PUBMED: 22511692] ">Basch 2012</a>; <a href="./references#CD010298-bbs2-0051" title="GabrielSE , NormandSL . Getting the methods right‐‐the foundation of patient‐centered outcomes research. New England Journal of Medicine2012;367(9):787‐90. [PUBMED: 22830434] ">Gabriel 2012</a>; <a href="./references#CD010298-bbs2-0109" title='Patient‐Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: "Our questions, our decisions: Standards for patient‐centered outcomes research", 2012. http://www.pcori.org/assets/Preliminary‐Draft‐Methodology‐Report.pdf (accessed 1 April 2013):1‐61. '>PCORI 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010298-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010298-sec-0022"></div> <div class="table" id="CD010298-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ruxolitinib compared with placebo for treating myelofibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ruxolitinib compared with placebo for treating MF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with treating MF<br/> <b>Settings:</b> Ambulatory<br/> <b>Intervention:</b> Ruxolitinib<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Ruxolitinib</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> <br/> (number of deaths at follow‐up (24 weeks<sup>1</sup>)) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> <br/> (25 to 89)<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.51</b> <br/> (0.27 to 0.98)<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not<br/> measured in the included<br/> study </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety (AE, adverse drug reaction): thrombocytopenia</b> <br/> Grades 3 or 4 according to National Cancer Institute<br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> <br/> (31 to 543) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 9.74</b> <br/> (2.32 to 40.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety (AE, adverse drug reaction): neutropenia</b> <br/> Grades 3 or 4 according to National Cancer Institute<br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> <br/> (20 to 249) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.57</b> <br/> (1.02 to 12.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> <br/> Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form<br/> Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> <br/> (229 to 919) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.82</b> <br/> (4.40 to 17.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in spleen size</b> <br/> Magnetic resonance imaging or computed tomography<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>419 per 1000</b> <br/> (59 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 64.58</b> <br/> (9.08 to 459.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is provided in footnote #2. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR:</b> hazard ratio. <b>AE:</b> adverse event; <b>MF:</b> myelofibrosis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> trial established the time of data cut‐off for its main outcome at 24 weeks.<br/> <sup>2</sup>Data obtained from deaths in the placebo group at the time of data cut‐off (24 weeks).<br/> <sup>3</sup>Data obtained from deaths in the intervention group at the time of data cut‐off (24 weeks).<br/> <sup>4</sup>See <a href="./references#CD010298-fig-0004" title="">Analysis 1.1</a>.<br/> <sup>5</sup><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> trial.<br/> <sup>6</sup>Downgraded one level due to limitations in the trial design or execution (high attrition bias).<br/> <sup>7</sup>Downgraded one level due to imprecision (low sample and number of events with an impact in the precision of the effect estimates). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010298-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ruxolitinib compared with best available therapy for treating myelofibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Ruxolitinib compared to best available therapy for treating MF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with treating MF<br/> <b>Settings:</b> Ambulatory<br/> <b>Intervention:</b> Ruxolitinib<br/> <b>Comparison:</b> Best available therapy<sup>1</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Best available therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Ruxolitinib</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> <br/> (number of deaths at follow‐up (48 weeks<sup>2</sup>)) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> <br/> (11 to 130)<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.70</b> <br/> (0.20 to 2.47)<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression Free Survival</b> <br/> (number of patients who had progression at follow‐up (48 weeks<sup>2</sup>)) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> <br/> (132 to 342)<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.81</b> <br/> (0.47 to 1.39)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety (AE, adverse drug reaction): anemia</b> <br/> Grades 3 or 4 according to National Cancer Institute<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>315 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>425 per 1000</b> <br/> (287 to 627) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.35</b> <br/> (0.91 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety (AE, adverse drug reaction): thrombocytopenia</b> <br/> Grades 3 or 4 according to National Cancer Institute<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 1000</b> <br/> (30 to 225) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> <br/> (0.44 to 3.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> <br/> European Organization for Research and Treatment of Cancer quality of life questionnaire core model. Scores ranges from 0 to 100. Scale from: 0 to 100.<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life in the intervention groups was<br/> <b>7.6 higher</b> <br/> (0.35 to 14.85 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in spleen size</b> <br/> Magnetic resonance imaging or computed tomography<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 41.78</b> <br/> (2.61 to 669.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is provided in footnote #3. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR:</b> hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>.<br/> <sup>2</sup><a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> trial established the time of data cut‐off for its main outcome at 48 weeks.<br/> <sup>3</sup>Data obtained from deaths in the best available therapy group at the time of data cut‐off (48 weeks).<br/> <sup>4</sup>Data obtained from deaths in the intervention group at the time of data cut‐off (48 weeks).<br/> <sup>5</sup>See <a href="./references#CD010298-fig-0011" title="">Analysis 2.1</a>.<br/> <sup>6</sup>Downgraded one level due to limitations in the trial design or execution (open design).<br/> <sup>7</sup>Downgraded one level due to imprecision (low sample and number of events with an impact in the precision of the effect estimates).<br/> <sup>8</sup>See <a href="./references#CD010298-fig-0012" title="">Analysis 2.2</a>. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010298-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010298-sec-0023"></div> <section id="CD010298-sec-0024"> <h3 class="title" id="CD010298-sec-0024">Description of the condition</h3> <p>Myelofibrosis (MF) is a bone marrow disorder characterized by excessive production of reticulin and collagen fibers (<a href="./references#CD010298-bbs2-0103" title="OstojicA , VrhovacR , VerstovsekS . Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Therapeutics and Clinical Risk Management2012;8:95‐103. [PUBMED: 22399854] ">Ostojic 2012</a>). It implies an increase in the bone marrow fiber content without referring to quantity or quality (reticulin versus collagen) (<a href="./references#CD010298-bbs2-0137" title="ThieleJ , KvasnickaHM . Myelofibrosis ‐ what's in a name? Consensus on definition and EUMNET grading. Pathobiology2007;74(2):89‐96. [PUBMED: 17587880] ">Thiele 2007</a>). MF can be the outcome of several hematological conditions (i.e., as evolution of a previously known myeloproliferative neoplasm, chronic myeloid leukemia, polycythemia vera, or essential thrombocythemia) (<a href="./references#CD010298-bbs2-0034" title="CervantesF , PereiraA . Advances in the understanding and management of primary myelofibrosis. Current Opinion in Oncology2011;23(6):665‐71. [PUBMED: 21892083] ">Cervantes 2011</a>; <a href="./references#CD010298-bbs2-0074" title="HoffmanR , XuM , BarosiG . Primary myelofibrosis. In: Hoffman , Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125‐47. [ISBN 978‐0‐443‐06715‐0] ">Hoffman 2008</a>) and non‐hematological conditions (metastatic cancer, infections such as tuberculosis, fungal infections and HIV, metabolic disorders, radiation, toxins, etc.) (<a href="./references#CD010298-bbs2-0074" title="HoffmanR , XuM , BarosiG . Primary myelofibrosis. In: Hoffman , Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125‐47. [ISBN 978‐0‐443‐06715‐0] ">Hoffman 2008</a>). </p> <p>Primary myelofibrosis (PMF) is a chronic, malignant hematological disorder characterized by splenomegaly, leukoerythroblastosis, teardrop poikilocytosis (i.e., dacryocytes), some degree of marrow fibrosis, increased marrow microvessel density, and extramedullary hematopoiesis (<a href="./references#CD010298-bbs2-0074" title="HoffmanR , XuM , BarosiG . Primary myelofibrosis. In: Hoffman , Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125‐47. [ISBN 978‐0‐443‐06715‐0] ">Hoffman 2008</a>). PMF is associated with osteosclerosis, angiogenesis, and an abnormal cytokine expression (<a href="./references#CD010298-bbs2-0131" title="TefferiA . Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology2011;86(12):1017‐26. [PUBMED: 22086865] ">Tefferi 2011b</a>). </p> <p>PMF is an infrequent disease, with an estimated incidence in Western countries that ranges from 0.4 to 1.4 new cases per 100,000 people/year (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>). The average age at diagnosis of PMF is approximately 65 years, and most patients are diagnosed between 50 and 69 years of age (<a href="./references#CD010298-bbs2-0074" title="HoffmanR , XuM , BarosiG . Primary myelofibrosis. In: Hoffman , Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125‐47. [ISBN 978‐0‐443‐06715‐0] ">Hoffman 2008</a>). In several case series, men have been affected more frequently than women, but other trials have failed to confirm this male predominance (<a href="./references#CD010298-bbs2-0074" title="HoffmanR , XuM , BarosiG . Primary myelofibrosis. In: Hoffman , Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125‐47. [ISBN 978‐0‐443‐06715‐0] ">Hoffman 2008</a>). PMF has rarely been reported in the pediatric age group (<a href="./references#CD010298-bbs2-0074" title="HoffmanR , XuM , BarosiG . Primary myelofibrosis. In: Hoffman , Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125‐47. [ISBN 978‐0‐443‐06715‐0] ">Hoffman 2008</a>). </p> <p>The clinical features of PMF include severe anemia, marked hepatosplenomegaly, constitutional symptoms (e.g., fatigue, night sweats, fever), cachexia, bone pain, splenic infarct, pruritus, thrombosis, and bleeding (<a href="./references#CD010298-bbs2-0131" title="TefferiA . Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology2011;86(12):1017‐26. [PUBMED: 22086865] ">Tefferi 2011b</a>). The main causes of the anemia and organomegaly are ineffective erythropoiesis and extramedullary hematopoiesis, respectively (<a href="./references#CD010298-bbs2-0131" title="TefferiA . Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology2011;86(12):1017‐26. [PUBMED: 22086865] ">Tefferi 2011b</a>). Other disease complications include symptomatic portal hypertension, which may lead to variceal bleeding or ascites, and non‐hepatosplenic extramedullary hematopoiesis, which may lead to cord compression, ascites, pleural effusion, pulmonary hypertension, or diffuse extremity pain (<a href="./references#CD010298-bbs2-0131" title="TefferiA . Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology2011;86(12):1017‐26. [PUBMED: 22086865] ">Tefferi 2011b</a>). These other complications are caused by aberrant cytokine production by clonal cells and host immune reaction contributing to PMF‐associated bone marrow stromal changes, ineffective erythropoiesis, extramedullary hematopoiesis, cachexia, and constitutional symptoms (<a href="./references#CD010298-bbs2-0131" title="TefferiA . Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology2011;86(12):1017‐26. [PUBMED: 22086865] ">Tefferi 2011b</a>). PMF is associated with cytogenetic abnormalities such as deletion of the long arm of chromosome 20 (20q‐), deletion of chromosome 13q (13q), trisomy 8 and 9, and abnormalities of chromosome 1 including duplication 1q (<a href="./references#CD010298-bbs2-0075" title="HusseinK , VanDykeDL , TefferiA . Conventional cytogenetics in myelofibrosis: literature review and discussion. European Journal of Haematology2009;82(5):329‐38. [PUBMED: 19141119] ">Hussein 2009</a>). </p> <p>Current diagnosis of MF is based on the World Health Organization (WHO) criteria and involves a composite assessment of clinical and laboratory features (<a href="./references#CD010298-bbs2-0130" title="TefferiA . How I treat myelofibrosis. Blood2011;117(13):3494‐504. [PUBMED: 21200024] ">Tefferi 2011a</a>). These criteria include major criteria (megakaryocyte proliferation and atypia accompanied by either reticulin, or collagen fibrosis, or both, or not meeting WHO criteria for chronic myelogenous leukemia, polycythemia vera, myelodysplastic syndromes), or other myeloid neoplasm, and demonstration of Janus kinase‐2 (guanine‐to‐thymidine substitution, which results in a change of valine for phenylalanine at codon 617), or a myeloproliferative leukemia virus oncogene mutation, occurring in 60% and 5% to 10% of the patients, respectively, and other myeloproliferative neoplasm‐associated molecular abnormalities (i.e. CBL, ASXL1, TET2, and EZH2), or clonal markers (particularly trisomy 9 or 13q−) that distinguish PMF from reactive marrow fibrosis (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>; <a href="./references#CD010298-bbs2-0144" title="WenQ , GoldensonB , CrispinoJD . Normal and malignant megakaryopoiesis. Expert Reviews in Molecular Medicine2011;13:e32. [PUBMED: 22018018] ">Wen 2011</a>). Additionally, the presence of minor criteria (leukoerythroblastosis, increased serum lactate dehydrogenase level, anemia, and palpable splenomegaly) (<a href="./references#CD010298-bbs2-0130" title="TefferiA . How I treat myelofibrosis. Blood2011;117(13):3494‐504. [PUBMED: 21200024] ">Tefferi 2011a</a>). PMF diagnosis requires meeting all three major criteria and two minor criteria (<a href="./references#CD010298-bbs2-0130" title="TefferiA . How I treat myelofibrosis. Blood2011;117(13):3494‐504. [PUBMED: 21200024] ">Tefferi 2011a</a>). </p> <p><a href="./appendices#CD010298-sec-0123">Appendix 1</a> shows the International Working Group for Myeloproliferative Neoplasms Research and Treatment Recommended Criteria for Post‐Polycythemia Vera and Post‐Essential Thrombocythemia Myelofibrosis (<a href="./references#CD010298-bbs2-0024" title="BarosiG , MesaRA , ThieleJ , CervantesF , CampbellPJ , VerstovsekS , et al. Proposed criteria for the diagnosis of post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia2008;22(2):437‐8. [PUBMED: 17728787] ">Barosi 2008</a>; <a href="./references#CD010298-bbs2-0130" title="TefferiA . How I treat myelofibrosis. Blood2011;117(13):3494‐504. [PUBMED: 21200024] ">Tefferi 2011a</a>). </p> <p>European Consensus Criteria for grading of MF is based on subjective evaluation of amount and distribution of reticulin and collagen in bone marrow. It is as follows: <i>MF‐0</i> (scattered linear reticulin with no intersections (crossovers) corresponding to normal bone marrow), MF<i>‐1</i> (loose network of reticulin with many intersections, especially in perivascular areas), MF<i>‐2</i> (diffuse and dense increase in reticulin with extensive intersections, occasionally with focal bundles of collagen, or focal osteosclerosis, or both) and MF<i>‐3</i> (diffuse and dense increase in reticulin with extensive intersections and coarse bundles of collagen, often associated with osteosclerosis) (<a href="./references#CD010298-bbs2-0074" title="HoffmanR , XuM , BarosiG . Primary myelofibrosis. In: Hoffman , Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125‐47. [ISBN 978‐0‐443‐06715‐0] ">Hoffman 2008</a>; <a href="./references#CD010298-bbs2-0136" title="ThieleJ , KvasnickaHM , FacchettiF , FrancoV , van derWaltJ , OraziA . European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica2005;90(8):1128‐32. [PUBMED: 16079113] ">Thiele 2005</a>; <a href="./references#CD010298-bbs2-0137" title="ThieleJ , KvasnickaHM . Myelofibrosis ‐ what's in a name? Consensus on definition and EUMNET grading. Pathobiology2007;74(2):89‐96. [PUBMED: 17587880] ">Thiele 2007</a>). </p> <p>PMF is associated with a low quality of life (<a href="./references#CD010298-bbs2-0091" title="MesaRA , SchwagerS , RadiaD , ChevilleA , HusseinK , NiblackJ , et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence‐based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research2009;33(9):1199‐203. [PUBMED: 19250674] ">Mesa 2009b</a>). The prognosis at the time of diagnosis is based on the International Prognostic Scoring System developed by International Working Group for Myeloproliferative Neaplasms Research and Treatment (<a href="./references#CD010298-bbs2-0033" title="CervantesF , DupriezB , PereiraA , PassamontiF , ReillyJT , MorraE , et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood2009;113(13):2895‐901. [PUBMED: 18988864] ">Cervantes 2009</a>). The International Prognostic Scoring System includes age (&gt; 65 years), constitutional symptoms, hemoglobin (&lt; 10 g/dL), white blood cell count (&gt; 25 x 10<sup>9</sup>/L), and blood blasts (≥ 1%) (<a href="./references#CD010298-bbs2-0106" title="PassamontiF , CervantesF , VannucchiAM , MorraE , RumiE , PereiraA , et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG‐MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood2010;115(9):1703‐8. [PUBMED: 20008785] ">Passamonti 2010</a>). International Working Group for Myeloproliferative Neoplasms Research and Treatment developed the Dynamic Prognostic Model with the same prognostic variables generated by International Prognostic Scoring System which can be applied at any time during the disease course (<a href="./references#CD010298-bbs2-0106" title="PassamontiF , CervantesF , VannucchiAM , MorraE , RumiE , PereiraA , et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG‐MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood2010;115(9):1703‐8. [PUBMED: 20008785] ">Passamonti 2010</a>). PMF progress to leukemia in ∼20% of patients, while others die because of comorbid conditions, including cardiovascular events (<a href="./references#CD010298-bbs2-0023" title="BarbuiT , CarobbioA , CervantesF , VannucchiAM , GuglielmelliP , AntonioliE , et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood2010;115(4):778‐82. [PUBMED: 19965680] ">Barbui 2010</a>), infection, or bleeding (<a href="./references#CD010298-bbs2-0131" title="TefferiA . Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology2011;86(12):1017‐26. [PUBMED: 22086865] ">Tefferi 2011b</a>). The median overall survival is 11.3 years for low risk, 7.9 years for intermediate‐1 risk, 4.0 years for intermediate‐2 risk, and 2.3 years for high‐risk MF (<a href="./references#CD010298-bbs2-0033" title="CervantesF , DupriezB , PereiraA , PassamontiF , ReillyJT , MorraE , et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood2009;113(13):2895‐901. [PUBMED: 18988864] ">Cervantes 2009</a>). </p> <p>In this Cochrane Review we included MF as a result of both hematological and non‐hematological conditions. We have provided a glossary of medical terms in <a href="./appendices#CD010298-sec-0130">Appendix 2</a>. </p> </section> <section id="CD010298-sec-0025"> <h3 class="title" id="CD010298-sec-0025">Description of the intervention</h3> <p>Allogeneic stem cell transplantation is the only curative option for patients with PMF who have an appropriate donor available (<a href="./references#CD010298-bbs2-0074" title="HoffmanR , XuM , BarosiG . Primary myelofibrosis. In: Hoffman , Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125‐47. [ISBN 978‐0‐443‐06715‐0] ">Hoffman 2008</a>; <a href="./references#CD010298-bbs2-0102" title="OstojicA , VrhovacR , VerstovsekS . Ruxolitinib for the treatment of myelofibrosis. Drugs of Today2011;47(11):817‐27. [PUBMED: 22146225] ">Ostojic 2011b</a>). However, allogeneic stem cell transplantation is a reasonable option for only a small percentage of eligible patients (i.e., those who are young and unburdened by other co‐morbidities) (<a href="./references#CD010298-bbs2-0102" title="OstojicA , VrhovacR , VerstovsekS . Ruxolitinib for the treatment of myelofibrosis. Drugs of Today2011;47(11):817‐27. [PUBMED: 22146225] ">Ostojic 2011b</a>). A conservative approach is generally accepted with observation of asymptomatic patients and therapeutic intervention for those who have symptoms (<a href="./references#CD010298-bbs2-0074" title="HoffmanR , XuM , BarosiG . Primary myelofibrosis. In: Hoffman , Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125‐47. [ISBN 978‐0‐443‐06715‐0] ">Hoffman 2008</a>). Current treatment regimens are mainly palliative and have not demonstrated a major benefit in overall survival (<a href="./references#CD010298-bbs2-0102" title="OstojicA , VrhovacR , VerstovsekS . Ruxolitinib for the treatment of myelofibrosis. Drugs of Today2011;47(11):817‐27. [PUBMED: 22146225] ">Ostojic 2011b</a>). </p> <section id="CD010298-sec-0026"> <h4 class="title">Therapy for treating anemia</h4> <p> <ol id="CD010298-list-0001"> <li> <p>Androgens (nandrolone, fluoxymesterone, methandrostenolone, oxymetholone, methenolone, and danazol) stimulate hematopoietic system by various mechanisms including stimulation of erythropoietin release, increasing bone marrow activity and iron incorporation into the red cells (<a href="./references#CD010298-bbs2-0125" title="ShahaniS , Braga‐BasariaM , MaggioM , BasariaS . Androgens and erythropoiesis: past and present. Journal of Endocrinological Investigation2009;32(8):704‐16. [PUBMED: 19494706] ">Shahani 2009</a>). It has been reported to improve the anemia in patients with MF in 30 to 60% of cases (<a href="./references#CD010298-bbs2-0025" title="BarosiG , CervantesF , Ben‐YehudaD , PanagiotidisP , PerezJR , Orlando‐HarperND , et al. A ruxolitinib individual supply program for patients with primary myelofibrosis, post‐polycythemia vera myelofibrosis, or post‐essential thrombocythemia myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118:5170. ">Barosi 2011a</a>). </p> </li> <li> <p>Recombinant human erythropoietin and darbepoetin alfa are growth factors with similar mechanisms of action as erythropoietin (<a href="./references#CD010298-bbs2-0044" title="DonnellyS . Why is erythropoietin made in the kidney? The kidney functions as a critmeter. American Journal of Kidney Diseases2001;38(2):415‐25. [PUBMED: 11479173] ">Donnelly 2001</a>). Darbepoetin alfa is an analog of recombinant human erythropoietin with a long half‐life that requires less frequent administration (once weekly or every other week) (<a href="./references#CD010298-bbs2-0032" title="CasesA . Darbepoetin alfa: a novel erythropoiesis‐stimulating protein. Drugs of Today2003;39(7):477‐95. [PUBMED: 12973399] ">Cases 2003</a>). The response rates of these drugs ranged from 16% to 60% (Barosi 2011b). However, there is an unexpected association between erythropoietin‐stimulating agents and danazol with leukemic transformation in MF (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>). </p> </li> <li> <p>Thalidomide and its analogs, lenalidomide and pomalidomide, have anti‐angiogenetic and immunomodulatory activities and have been used previously for MF (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>; <a href="./references#CD010298-bbs2-0129" title="TefferiA , VerstovsekS , BarosiG , PassamontiF , RobozGJ , GisslingerH , et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of Clinical Oncology2009;27(27):4563‐9. [PUBMED: 19652059] ">Tefferi 2009</a>). </p> </li> </ol> </p> </section> <section id="CD010298-sec-0027"> <h4 class="title">Splenomegaly and myeloproliferation treatment</h4> <p>Overall, this approach decreases the immature circulating myeloid pool accumulating in the spleen. The following interventions have been previously described for these purposes: </p> <p> <ol id="CD010298-list-0002"> <li> <p>Hydroxyurea limits the deoxyribonucleic acid biosynthesis. The studies using hydroxycarbamide have reported a response on splenomegaly in up to 40% of treated cause (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>). </p> </li> <li> <p>Chlorambucil, 6‐thioguanine, melphalan, and busulfan are oral alkylating agents. Use of the last two drugs is limited by the increased risk of blast transformation and unfavorable toxicity profile (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>). </p> </li> <li> <p>Interferon biologic response modifier inhibits in vitro proliferation of hematopoietic progenitors, particularly of the megakaryocytic lineage (Barosi 2011b). It can be useful in suppressing thrombocytosis and inhibiting the activity of platelet derived growth factor which stimulates the proliferation of fibroblasts (<a href="./references#CD010298-bbs2-0074" title="HoffmanR , XuM , BarosiG . Primary myelofibrosis. In: Hoffman , Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125‐47. [ISBN 978‐0‐443‐06715‐0] ">Hoffman 2008</a>). </p> </li> <li> <p>Thalidomide analogs are immunomodulator drugs. Two studies conducted for assessing lenalidomide in patients with MF have reported a reduction of spleen size ranging between 10% and 42% (<a href="./references#CD010298-bbs2-0093" title="MesaRA , YaoX , CripeLD , LiCY , LitzowM , PaiettaE , et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood2010;116(22):4436‐8. [PUBMED: 20651074] ">Mesa 2010b</a>; <a href="./references#CD010298-bbs2-0116" title="Quintás‐CardamaA , KantarjianHM , ManshouriT , ThomasD , CortesJ , RavandiF , et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. Journal of Clinical Oncology2009;27(28):4760‐6. [PUBMED: 19720904] ">Quintás‐Cardama 2009</a>). Two studies on pomalidomide showed a poor response on spleen size (<a href="./references#CD010298-bbs2-0028" title="BegnaKH , MesaRA , PardananiA , HoganWJ , LitzowMR , McClureRF , et al. A phase‐2 trial of low‐dose pomalidomide in myelofibrosis. Leukemia2011;25(2):301‐4. [PUBMED: 21052089] ">Begna 2011</a>; <a href="./references#CD010298-bbs2-0092" title="MesaRA , PardananiAD , HusseinK , WuW , SchwagerS , LitzowMR , et al. Phase1/‐2 study of Pomalidomide in myelofibrosis. American Journal of Hematology2010;85(2):129‐30. [PUBMED: 20052748] ">Mesa 2010a</a>). </p> </li> <li> <p>Janus kinase inhibitors have been reported for treating MF (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>; <a href="./references#CD010298-bbs2-0003" title="GeyerH , CannonK , KnightE , FaubleV , CamorianoJ , EmanuelR , et al. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Leukemia &amp; Lymphoma2014;55(1):195‐7. [PUBMED: 23647081] VerstovsekS . Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. Leukemia &amp; Lymphoma2014;55(1):5‐6. [PUBMED: 23829281] ">Geyer 2014</a>; <a href="./references#CD010298-bbs2-0094" title="MesaRA . The evolving treatment paradigm in myelofibrosis. Leukemia &amp; Lymphoma2013;54(2):242‐51. [PUBMED: 22793267] ">Mesa 2012a</a>; <a href="./references#CD010298-bbs2-0118" title="RandhawaJ , OstojicA , VrhovacR , AtallahE , VerstovsekS . Splenomegaly in myelofibrosis‐new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. Journal of Hematology &amp; Oncology2012;5:43. [PUBMED: 22852872] ">Randhawa 2012</a>). In November 2011, the U.S. Food and Drug Administration (FDA) approved the use of ruxolitinib, a JAK‐1‐ and JAK‐2‐selective inhibitor, for the treatment of patients with intermediate or high‐risk MF (<a href="./references#CD010298-bbs2-0042" title="DeisserothA , KaminskasE , GrilloJ , ChenW , SaberH , LuHL , et al. U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high‐risk myelofibrosis. Clinical Cancer Research2012;18(12):3212‐7. [PUBMED: 22544377] ">Deisseroth 2012</a>; <a href="./references#CD010298-bbs2-0088" title="MascarenhasJ , HoffmanR . Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clinical Cancer Research2012;18(11):3008‐14. [PUBMED: 22474318] ">Mascarenhas 2012</a>; <a href="./references#CD010298-bbs2-0118" title="RandhawaJ , OstojicA , VrhovacR , AtallahE , VerstovsekS . Splenomegaly in myelofibrosis‐new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. Journal of Hematology &amp; Oncology2012;5:43. [PUBMED: 22852872] ">Randhawa 2012</a>). Two randomized controlled trials (RCTs) have been conducted for assessing the efficacy and safety of this drug in patients with MF (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). These RCTs have emphasized on surrogate end point (reduction in spleen volume) and quality of life. Both RCTs have shown significant reduction in spleen volume and enhancement in quality of life. Other JAK inhibitors, such as SAR302503, CYT387, SB1518, and TG101348 may become commercially available in the near future (<a href="./references#CD010298-bbs2-0003" title="GeyerH , CannonK , KnightE , FaubleV , CamorianoJ , EmanuelR , et al. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Leukemia &amp; Lymphoma2014;55(1):195‐7. [PUBMED: 23647081] VerstovsekS . Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. Leukemia &amp; Lymphoma2014;55(1):5‐6. [PUBMED: 23829281] ">Geyer 2014</a>; <a href="./references#CD010298-bbs2-0094" title="MesaRA . The evolving treatment paradigm in myelofibrosis. Leukemia &amp; Lymphoma2013;54(2):242‐51. [PUBMED: 22793267] ">Mesa 2012a</a>). </p> </li> </ol> </p> </section> </section> <section id="CD010298-sec-0028"> <h3 class="title" id="CD010298-sec-0028">How the intervention might work</h3> <p>The Janus family includes a cytoplasmic tyrosine kinases (JAK‐1, JAK‐2, JAK‐3, and TYK2) which mediates the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function (<a href="./references#CD010298-bbs2-0108" title="PastoreA , TemussiPA . The two faces of Janus: functional interactions and protein aggregation. Current Opinion in Structural Biology2012;22(1):30‐7. [PUBMED: 22155180] ">Pastore 2012</a>; <a href="./references#CD010298-bbs2-0124" title="SeaveyMM , DobrzanskiP . The many faces of Janus kinase. Biochemical Pharmacology2012;83(9):1136‐45. [PUBMED: 22209716] ">Seavey 2012</a>; <a href="./references#CD010298-bbs2-0126" title="SteinBL , CrispinoJD , MoliternoAR . Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Current Opinion in Oncology2011;23(6):609‐16. [PUBMED: 21993415] ">Stein 2011</a>; <a href="./references#CD010298-bbs2-0138" title="ThompsonJE . JAK protein kinase inhibitors. Drug News &amp; Perspectives2005;18(5):305‐10. [PUBMED: 16193102] ">Thompson 2005</a>). JAK‐1 plays a major role in the signaling of a number of pro‐inflammatory cytokines; JAK‐2 is used primarily by receptors for hematopoietic growth factors; JAK‐3 primarily mediates immune function, whereas TYK2 functions in association with JAK‐2 or JAK‐3 to transduce signaling of cytokines such as interleukin 12 (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>; <a href="./references#CD010298-bbs2-0108" title="PastoreA , TemussiPA . The two faces of Janus: functional interactions and protein aggregation. Current Opinion in Structural Biology2012;22(1):30‐7. [PUBMED: 22155180] ">Pastore 2012</a>; <a href="./references#CD010298-bbs2-0124" title="SeaveyMM , DobrzanskiP . The many faces of Janus kinase. Biochemical Pharmacology2012;83(9):1136‐45. [PUBMED: 22209716] ">Seavey 2012</a>; <a href="./references#CD010298-bbs2-0126" title="SteinBL , CrispinoJD , MoliternoAR . Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Current Opinion in Oncology2011;23(6):609‐16. [PUBMED: 21993415] ">Stein 2011</a>; <a href="./references#CD010298-bbs2-0138" title="ThompsonJE . JAK protein kinase inhibitors. Drug News &amp; Perspectives2005;18(5):305‐10. [PUBMED: 16193102] ">Thompson 2005</a>). </p> <p>Several reviews on JAK inhibitor therapy for MF have been published (<a href="./references#CD010298-bbs2-0102" title="OstojicA , VrhovacR , VerstovsekS . Ruxolitinib for the treatment of myelofibrosis. Drugs of Today2011;47(11):817‐27. [PUBMED: 22146225] ">Ostojic 2011b</a>; <a href="./references#CD010298-bbs2-0101" title="OstojicA , VrhovacR , VerstovsekS . Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncology2011;7(9):1035‐43. [PUBMED: 21919691] ">Ostojic 2011a</a>; <a href="./references#CD010298-bbs2-0009" title="PardananiA , GotlibJR , JamiesonC , CortesJE , TalpazM , StoneRM , et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Journal of Clinical Oncology2011;29(7):789‐96. [PUBMED: 21220608] PardananiAD , GotlibJ , JamiesonC , CortesJ , TalpazM , StoneRM , et al. A phase I study of TG101348, an orally bioavailable JAK2‐selective inhibitor, in patients with myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood (ASH Annual Meeting Abstracts). 2009; Vol. 112: 755. ">Pardanani 2011a</a>; <a href="./references#CD010298-bbs2-0104" title="PardananiA , TefferiA . Targeting myeloproliferative neoplasms with JAK inhibitors. Current Opinion in Hematology2011;18(2):105‐10. [PUBMED: 21245760] ">Pardanani 2011b</a>; <a href="./references#CD010298-bbs2-0107" title="PassamontiF , MaffioliM , CaramazzaD . New generation small‐molecule inhibitors in myeloproliferative neoplasms. Current Opinion in Hematology2012;19(2):117‐23. [PUBMED: 22227528] ">Passamonti 2012</a>; <a href="./references#CD010298-bbs2-0126" title="SteinBL , CrispinoJD , MoliternoAR . Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Current Opinion in Oncology2011;23(6):609‐16. [PUBMED: 21993415] ">Stein 2011</a>; <a href="./references#CD010298-bbs2-0134" title="TefferiA , PardananiA . JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Reviews2011;25(5):229‐37. [PUBMED: 21742423] ">Tefferi 2011e</a>; <a href="./references#CD010298-bbs2-0135" title="TefferiA . JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood2012;119(12):2721‐30. [PUBMED: 22279053] ">Tefferi 2012</a>). Ruxolitinib, which modulates the abnormal cytokine production and signaling, plays a major role in pathogenesis of MF (<a href="./references#CD010298-bbs2-0143" title="VannucchiAM . How do JAK2‐inhibitors work in myelofibrosis: an alternative hypothesis. Leukemia Research2009;33(12):1581‐3. [PUBMED: 19573914] ">Vannucchi 2009</a>). Nevertheless, the clinical effect of JAK‐2‐inhibitors seen in people with MF seems to reflect the effect of the drug over normal hematopoiesis with an unmutated JAK‐2‐allele rather than on the MPN‐clone (myeloproliferative neoplasm) with the mutated JAK‐2‐allele (<a href="./references#CD010298-bbs2-0090" title="MesaR , GaleRP . Hypothesis: how do JAK2‐inhibitors work in myelofibrosis. Leukemia Research2009;33(9):1156‐7. [PUBMED: 19450878] ">Mesa 2009a</a>). Ruxolitinib was initially used in a phase 1/2 trial including 153 patients with MF (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>; <a href="./references#CD010298-bbs2-0131" title="TefferiA . Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology2011;86(12):1017‐26. [PUBMED: 22086865] ">Tefferi 2011b</a>; <a href="./references#CD010298-bbs2-0103" title="OstojicA , VrhovacR , VerstovsekS . Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Therapeutics and Clinical Risk Management2012;8:95‐103. [PUBMED: 22399854] ">Ostojic 2012</a>). In this trial, treatment was well tolerated, with dose‐limiting toxicity represented by reversible thrombocytopenia. Ruxolitinib has shown significant clinical response with a ≥ 50% reduction of splenomegaly in half of the patients and rapid improvement of constitutional symptoms, cachexia, and exercise tolerance (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>; <a href="./references#CD010298-bbs2-0131" title="TefferiA . Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology2011;86(12):1017‐26. [PUBMED: 22086865] ">Tefferi 2011b</a>; <a href="./references#CD010298-bbs2-0103" title="OstojicA , VrhovacR , VerstovsekS . Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Therapeutics and Clinical Risk Management2012;8:95‐103. [PUBMED: 22399854] ">Ostojic 2012</a>).  After a single oral dose, &gt; 95% of the ruxolitinib is absorbed, and &gt; 97% becomes available bounding to plasma proteins. The terminal half‐life is two to three hours (<a href="./references#CD010298-bbs2-0103" title="OstojicA , VrhovacR , VerstovsekS . Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Therapeutics and Clinical Risk Management2012;8:95‐103. [PUBMED: 22399854] ">Ostojic 2012</a>). Ruxolitinib is metabolized predominantly in the liver, and its metabolites are mainly excreted in urine (<a href="./references#CD010298-bbs2-0103" title="OstojicA , VrhovacR , VerstovsekS . Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Therapeutics and Clinical Risk Management2012;8:95‐103. [PUBMED: 22399854] ">Ostojic 2012</a>). Its adverse events include thrombocytopenia, anemia, and a 'cytokine rebound reaction' upon drug discontinuation, characterized by acute relapse of symptoms and splenomegaly (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>; <a href="./references#CD010298-bbs2-0132" title="TefferiA , LitzowMR , PardananiA . Long‐term outcome of treatment with ruxolitinib in myelofibrosis. New England Journal of Medicine2011;365(15):1455‐7. [PUBMED: 21995409] ">Tefferi 2011c</a>; <a href="./references#CD010298-bbs2-0133" title="TefferiA , PardananiA . Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clinic Proceedings2011;86(12):1188‐91. [PUBMED: 22034658] ">Tefferi 2011d</a>). </p> </section> <section id="CD010298-sec-0029"> <h3 class="title" id="CD010298-sec-0029">Why it is important to do this review</h3> <p>We conducted this Cochrane Review for several reasons. The primary goals of the therapy for MF are to alleviate the symptoms and to achieve an improvement in the patients' quality of life, but it lacks any real impact on overall survival and progression‐free survival (<a href="./references#CD010298-bbs2-0026" title="BarosiG , RostiV , VannucchiAM . Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy2011;12(10):1597‐611. [PUBMED: 21457082] ">Barosi 2011b</a>; <a href="./references#CD010298-bbs2-0117" title="QureshiM , HarrisonC . Management of myelofibrosis ‐ where next?. Expert Opinion on Pharmacotherapy2011;12(10):1453‐5. [PUBMED: 21651445] ">Qureshi 2011</a>). Controversy exists if the current trial endpoints capture a tangible benefit for MF patients (<a href="./references#CD010298-bbs2-0105" title="PardananiA . Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Leukemia2012;26(7):1449‐51. [PUBMED: 22285996] ">Pardanani 2012</a>). Therefore, we need to perform a critical appraisal of the RCTs conducted to assess ruxolitinib in patients with MF (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). Furthermore, this drug has been associated with serious adverse events (anemia and thrombocytopenia) (<a href="./references#CD010298-bbs2-0132" title="TefferiA , LitzowMR , PardananiA . Long‐term outcome of treatment with ruxolitinib in myelofibrosis. New England Journal of Medicine2011;365(15):1455‐7. [PUBMED: 21995409] ">Tefferi 2011c</a>; <a href="./references#CD010298-bbs2-0133" title="TefferiA , PardananiA . Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clinic Proceedings2011;86(12):1188‐91. [PUBMED: 22034658] ">Tefferi 2011d</a>). Ruxolitinib is expensive and costs USD7,000 per month of treatment, or USD84,000 per year, for the insured patient (<a href="./references#CD010298-bbs2-0095" title="MesaRA , YasothanU , KirkpatrickP . Ruxolitinib. Nature Reviews. Drug Discovery2012;11(2):103‐4. [PUBMED: 22293561] ">Mesa 2012b</a>). </p> <p>In this Cochrane Review we have included a rigorous assessment of the risk of bias, using most up‐to‐date evidence to help clinicians making informed decisions on the use of Janus kinase‐1 and Janus kinase‐2 inhibitors for treating patients with MF due to hematological or non‐hematological conditions. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010298-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010298-sec-0030"></div> <p>To determine the clinical benefits and harms of Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis secondary to hematological or non‐hematological conditions. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010298-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010298-sec-0031"></div> <section id="CD010298-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010298-sec-0033"> <h4 class="title">Types of studies</h4> <p>We included RCTs irrespective of their publication status (unpublished or published as an article, an abstract, or a letter) and language. No limits were applied with respect to period of follow‐up. We excluded quasi‐RCTs. </p> </section> <section id="CD010298-sec-0034"> <h4 class="title">Types of participants</h4> <p>We included patients with a confirmed diagnosis of MF caused by hematological and non‐hematological conditions, irrespective of their age, gender, or ethnicity. </p> </section> <section id="CD010298-sec-0035"> <h4 class="title">Types of interventions</h4> <section id="CD010298-sec-0036"> <h5 class="title">Intervention</h5> <p>We compared ruxolitinib with placebo or best available therapy in this review. In future updates, we will also include trials assessing the following JAK‐1 and 2 inhibitors: </p> <p> <ul id="CD010298-list-0003"> <li> <p>SAR302503.</p> </li> <li> <p>CYT387.</p> </li> <li> <p>SB1518.</p> </li> <li> <p>TG101348.</p> </li> </ul> </p> </section> <section id="CD010298-sec-0037"> <h5 class="title">Comparisons</h5> <p> <ul id="CD010298-list-0004"> <li> <p>Placebo.</p> </li> <li> <p>Other treatments.</p> </li> <li> <p>Head‐to‐head comparisons of JAK inhibitors.</p> </li> </ul> </p> </section> </section> <section id="CD010298-sec-0038"> <h4 class="title">Types of outcome measures</h4> <section id="CD010298-sec-0039"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010298-list-0005"> <li> <p>Overall survival: the time from randomization until death from any cause (<a href="./references#CD010298-bbs2-0046" title="Food , DrugAdministration . Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. 2007. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf (accessed 22 March 2012). ">FDA 2007</a>). </p> </li> <li> <p>Progression‐free survival: the time from randomization until objective tumor progression or death (<a href="./references#CD010298-bbs2-0046" title="Food , DrugAdministration . Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. 2007. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf (accessed 22 March 2012). ">FDA 2007</a>). </p> </li> <li> <p>Safety:</p> </li> </ol> <ul class="plain" id="CD010298-list-0006"> <li> <ul id="CD010298-list-0007"> <li> <p>Adverse event: "any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment" (<a href="./references#CD010298-bbs2-0099" title="NebekerJR , BarachP , SamoreMH . Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine2004;140(10):795‐801. [PUBMED: 15148066] ">Nebeker 2004</a>). </p> </li> <li> <p>Adverse drug reaction: "a response to a drug which is noxious and uninitiated and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiologic functions" (<a href="./references#CD010298-bbs2-0099" title="NebekerJR , BarachP , SamoreMH . Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine2004;140(10):795‐801. [PUBMED: 15148066] ">Nebeker 2004</a>). </p> </li> </ul> </li> </ul> </p> </section> <section id="CD010298-sec-0040"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010298-list-0008"> <li> <p>Health‐related quality of life assessed by MF Symptom Assessment Form (MFSAF) (<a href="./references#CD010298-bbs2-0091" title="MesaRA , SchwagerS , RadiaD , ChevilleA , HusseinK , NiblackJ , et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence‐based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research2009;33(9):1199‐203. [PUBMED: 19250674] ">Mesa 2009b</a>) or any other validated scale. </p> </li> <li> <p>Leukemia‐free survival.</p> </li> <li> <p>Reduction in spleen size</p> </li> <li> <p>Anemia response defined as an increasing of ≥ 1 g/L at the end of follow‐up.</p> </li> </ol> </p> </section> </section> </section> <section id="CD010298-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <p>We developed the search strategy as indicated in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010298-bbs2-0084" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefevbre 2011</a>). We conducted this process with the support of the Cochrane Haematological Malignancies Group Trials Search Co‐ordinator and adjusted it for each database we searched. </p> <section id="CD010298-sec-0042"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases:</p> <p> <ul id="CD010298-list-0009"> <li> <p><a href="http://www.thecochranelibrary.com/" target="_blank">Cochrane Central Register of Controlled Trials</a> (CENTRAL, the Cochrane Library 2014, Issue 11). </p> </li> <li> <p><a href="http://ovidsp.tx.ovid.com/sp-3.8.1a/ovidweb.cgi?%26S=GCGMFPKKIDDDDBHDNCOKKEFBEIHIAA00%26New+Database=Single|8" target="_blank">MEDLINE (Ovid) and Ovid MEDLINE(R) In‐Process &amp; Other Non‐Indexed Citations</a> (from 1946 to 13 November 2014). </p> </li> <li> <p><a href="http://www.elsevier.com/online-tools/embase" target="_blank">EMBASE</a> (OVID) (from 1980 to 12 January 2013). </p> </li> <li> <p><a href="http://lilacs.bvsalud.org/es/" target="_blank">LILACS</a> (from 1982 to 20 November 2014). </p> </li> </ul> </p> <p>See <a href="./appendices#CD010298-sec-0131">Appendix 3</a>; <a href="./appendices#CD010298-sec-0133">Appendix 4</a>; <a href="./appendices#CD010298-sec-0134">Appendix 5</a>; <a href="./appendices#CD010298-sec-0135">Appendix 6</a> for details. </p> </section> <section id="CD010298-sec-0043"> <h4 class="title">Searching other resources</h4> <p>We searched the following trial databases for ongoing and unpublished trials:</p> <p> <ol id="CD010298-list-0010"> <li> <p>WHO International Clinical Trials Registry Platform (WHO ICTRP) search portal (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>). </p> </li> <li> <p>The <i>metaR</i> egister of Controlled Trials (<i>m</i>RCT) (<a href="http://www.controlled-trials.com/mrct/" target="_blank">http://www.controlled‐trials.com/mrct/</a>) (<a href="./appendices#CD010298-sec-0136">Appendix 7</a>). </p> </li> </ol> </p> <p>We also searched conference proceedings:</p> <p> <ol id="CD010298-list-0011"> <li> <p>American Society of Hematology (ASH) (<a href="http://www.hematology.org/" target="_blank">http://www.hematology.org/</a>) (from 2009 to October 2013). </p> </li> <li> <p>European Hematology Association (EHA) (<a href="http://www.ehaweb.org/" target="_blank">http://www.ehaweb.org/</a>) (from 2009 to October 2013). </p> </li> <li> <p>American Society of Clinical Oncology (ASCO) (<a href="http://www.asco.org/" target="_blank">http://www.asco.org/</a>) (from 2009 to October 2013). </p> </li> <li> <p>European Society of Medical Oncology (ESMO) (<a href="http://www.esmo.org/" target="_blank">http://www.esmo.org/</a>) (from 2009 to October 2013). </p> </li> </ol> </p> <p>We also searched the following websites:</p> <p> <ol id="CD010298-list-0012"> <li> <p>FDA (<a href="http://www.fda.gov/" target="_blank">http://www.fda.gov/</a>). </p> </li> <li> <p>European Medicines Agency (<a href="http://www.ema.europa.eu/ema/" target="_blank">http://www.ema.europa.eu/ema/</a>). </p> </li> <li> <p><a href="http://www.epistemonikos.org/" target="_blank">http://www.epistemonikos.org/</a> (<a href="./appendices#CD010298-sec-0137">Appendix 8</a>). </p> </li> </ol> </p> <p>We handsearched the references of all identified included trials, relevant review articles, and current treatment guidelines. We did not apply any language restrictions. We used codes of pharmaceutical companies such as INCB018424, SAR302503, CYT387, SB1518, and TG101348 especially in abstract and trial register searches to identify closed or stopped studies, and brand names in search only if available. </p> </section> </section> <section id="CD010298-sec-0044"> <h3 class="title" id="CD010298-sec-0044">Data collection and analysis</h3> <p>We summarized data using standard Cochrane methodologies (<a href="./references#CD010298-bbs2-0072" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011d</a>). </p> <section id="CD010298-sec-0045"> <h4 class="title">Selection of studies</h4> <p>Regarding methods for study selection, we followed the steps delineated by the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010298-bbs2-0070" title="HigginsJPT , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>).<br/> Two authors (AMC and VA) screened the titles and abstracts identified from the above sources to identify potential studies for inclusion. If this could not be done satisfactorily from the title and abstract, a full text version was sought for assessment. We presented the results of the study selection as a flowchart according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) statement (<a href="./references#CD010298-bbs2-0097" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. [PUBMED: 19631508] ">Moher 2009</a>). </p> <p>We resolved any disagreement through discussion and consensus. We also contacted the authors of the trials to resolve any doubts about available information or in case of disagreements. </p> </section> <section id="CD010298-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>We extracted data adequately by collecting the following items: review, reviewer and study information, eligibility criteria, characteristics of participants (age, gender, country), trial design and funding, intervention duration and dosages, and outcomes. We assessed quality criteria according to risk of bias using the Cochrane's 'Risk of bias' assessment tool: random sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective reporting; and other bias (<a href="./references#CD010298-bbs2-0070" title="HigginsJPT , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> <p>For eligible trials, two review authors (AMC and VA) independently extracted the data using the agreed form. We resolved discrepancies through discussion. One review author (AMC) entered data into Cochrane's statistical software, <a href="./references#CD010298-bbs2-0119" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a> and two review authors (VA and IS) independently checked it for accuracy. </p> <p>We also contacted the corresponding trial authors to provide further details.</p> </section> <section id="CD010298-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (AMC, VA and IS) independently assessed the risk of bias in pairs of each trial using a simple form, and followed the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010298-bbs2-0069" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We resolved any discrepancies through discussion. </p> <p>We assessed the following domains as at low, unclear, or high risk of bias:</p> <p> <ol id="CD010298-list-0013"> <li> <p>Generation of allocation sequence.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding (of participants, personnel, and outcome assessors).</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective reporting.</p> </li> <li> <p>Other sources.</p> </li> </ol> </p> <section id="CD010298-sec-0048"> <h5 class="title">Overall risk of bias</h5> <p>We made explicit judgements about whether trials were at low, unclear, or high risk of bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010298-bbs2-0072" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011d</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it likely to have impact on the findings. As it is unlikely to find trials at low risk of bias in all items, we chose three core domains instead of all: generation of allocation sequence, incomplete outcome data, and selective reporting bias in order to classify a trial as at low, unclear, or high risk of bias. We would have conducted a sensitivity analyses for exploring the impact of the level of bias, if feasible (see <a href="#CD010298-sec-0056">Sensitivity analysis</a>). </p> </section> </section> <section id="CD010298-sec-0049"> <h4 class="title">Measures of treatment effect</h4> <p> <ol id="CD010298-list-0014"> <li> <p>For the time‐to‐event data, such as overall survival, progression‐free survival, leukemia‐free survival, we calculated hazard ratios (HRs) and 95% confidence intervals (95% CIs). We determined HRs for published data according to <a href="./references#CD010298-bbs2-0038" title="Biostat, Inc. Comprehensive Meta‐Analysis. Version 2.0. Englewood, NJ: Biostat, Inc, 2005. ">CMA 2005</a>. </p> </li> <li> <p>For the binary outcomes, such as safety and spleen size reduction (≥ 35%), we calculated the relative risk (RR) with 95% CIs. </p> </li> <li> <p>For the continuous outcomes, such as spleen size, we calculated the mean difference (MD) with 95% CIs. </p> </li> </ol> </p> </section> <section id="CD010298-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> assessed reduction in spleen size as a continuous variable using 79% of the original participants. However, the trial authors used all participants when they measured reduction in spleen size as a binary variable. We reported results using both approaches. We contacted the corresponding trial author for the missing continuous data on reduction in spleen size. </p> <p>In future updates, in case of missing data on participants or missing statistics (such as standard deviations), we will contact the trial authors. If unsuccessful, we will base our main analysis on completers but we will perform sensitivity analysis for worse and best case scenarios according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010298-bbs2-0071" title="HigginsJPT , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011c</a>). </p> </section> <section id="CD010298-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>We did not conduct a meta‐analysis because the comparison controls were different. If we had more than two included trials for each comparison, we would also have assessed statistical heterogeneity in each meta‐analysis using the T<sup>2</sup>, I<sup>2</sup> and Chi<sup>2</sup> statistics. We would have regarded heterogeneity as substantial if the I<sup>2</sup> statistic value was &gt; 30% and either T<sup>2</sup> was &gt; zero, or there was a low P value (&lt; 0.10) in the Chi<sup>2</sup> test for heterogeneity (<a href="./references#CD010298-bbs2-0041" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). In future updates we will measure heterogeneity if three or more trials are included. </p> </section> <section id="CD010298-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>Only two trials were available, so we did not explore publication bias.</p> <p>We would also have attempted to assess whether this Cochrane Review is subject to publication bias by using a funnel plot to graphically illustrate variability between trials. If we had detected asymmetry, we would have explored causes other than publication bias (e.g., selective outcome reporting, poor methodological quality in smaller studies, true heterogeneity) (<a href="./references#CD010298-bbs2-0072" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011d</a>). In future updates we will construct a funnel plot, provided we have ten or more RCTs for each comparison (<a href="./references#CD010298-bbs2-0127" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. [PUBMED: 21784880] ">Sterne 2011</a>). </p> </section> <section id="CD010298-sec-0053"> <h4 class="title">Data synthesis</h4> <p>Although we planned to conduct meta‐analyses, we ultimately only conducted a qualitative synthesis of the results from the two included trials. We did not pool data due to the huge differences between the control groups in the two included trials and follow‐up duration. </p> <p>In future versions of the review we plan to carry out statistical analyses using <a href="./references#CD010298-bbs2-0119" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a> software using random‐effects models according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010298-bbs2-0041" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> <section id="CD010298-sec-0054"> <h5 class="title">Summary of findings</h5> <p>We used the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to assess the quality of the body of evidence associated with all main outcomes (overall survival, progression‐free survival, safety (hematological adverse events), health‐related quality of life) (<a href="./references#CD010298-bbs2-0059" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines: 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [PUBMED: 21839614] ">Guyatt 2011c</a>), and we constructed a 'Summary of findings' table using <a href="./references#CD010298-bbs2-0054" title="McMaster University. GRADEpro. Version (19 March 2015). McMaster University, 2014. ">GRADEpro 2014</a> software. The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Evaluation of the quality of a body of evidence considers within study risk of bias, the directness of the evidence, heterogeneity in the data, precision of effect estimates, and risk of publication bias (<a href="./references#CD010298-bbs2-0022" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. [PUBMED: 21208779] ">Balshem 2011</a>; <a href="./references#CD010298-bbs2-0057" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011a</a>; <a href="./references#CD010298-bbs2-0058" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. [PUBMED: 21194891] ">Guyatt 2011b</a>; <a href="./references#CD010298-bbs2-0060" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. [PUBMED: 21803546] ">Guyatt 2011d</a>; <a href="./references#CD010298-bbs2-0061" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence ‐ indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. [PUBMED: 21802903] ">Guyatt 2011e</a>; <a href="./references#CD010298-bbs2-0062" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence ‐ publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. [PUBMED: 21802904] ">Guyatt 2011f</a>; <a href="./references#CD010298-bbs2-0063" title="GuyattGH , OxmanAD , SchünemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380‐2. [PUBMED: 21185693] ">Guyatt 2011g</a>; <a href="./references#CD010298-bbs2-0064" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. [PUBMED: 21802902] ">Guyatt 2011h</a>; <a href="./references#CD010298-bbs2-0065" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence ‐ study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. [PUBMED: 21247734] ">Guyatt 2011i</a>; <a href="./references#CD010298-bbs2-0066" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines 12. Preparing Summary of findings tables ‐ binary outcomes. Journal of Clinical Epidemiology2013;66(2):158‐72. [PUBMED: 22609141] ">Guyatt 2013</a>). </p> <p>We only included hematological adverse events because these are more relevant than non‐hematological adverse events (<a href="./full#CD010298-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010298-tbl-0002">summary of findings Table 2</a>). </p> <p>We used the number of deaths reported in <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> to estimate mortality in the 'Summary of findings' table as an approach of overall survival. However, it only was reported in the 'Summary of findings' table rather than in the review text. <a href="./references#CD010298-bbs2-0054" title="McMaster University. GRADEpro. Version (19 March 2015). McMaster University, 2014. ">GRADEpro 2014</a> does not allow estimation of either assumed or corresponding risks. </p> </section> </section> <section id="CD010298-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We would have used the following procedures (and will apply these for future updates, if possible). We had anticipated clinical heterogeneity in the intervention effect and we had proposed to conduct the following subgroup analyses: </p> <p> <ul id="CD010298-list-0015"> <li> <p>MF subtype:</p> <ul id="CD010298-list-0016"> <li> <p>PMF.</p> </li> <li> <p>Philadelphia‐chromosome‐negative myeloproliferative disorders: post‐polycythemia vera MF and post‐essential thrombocythemia MF. </p> </li> <li> <p>Secondary MF (such as cancer, tuberculosis, and radiation).</p> </li> </ul> </li> <li> <p>JAK‐2 V617F mutation status at screening.</p> </li> <li> <p>Previous MF therapy.</p> </li> <li> <p>Ruxolitinib versus other Janus kinase‐1 and Janus kinase‐2 inhibitors.</p> </li> </ul> </p> <p>These different variables justify subgroup analyses. In future updates we will perform subgroup analyses only for primary outcomes. </p> </section> <section id="CD010298-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>We would also have conducted sensitivity analysis according to <a href="./references#CD010298-bbs2-0072" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011d</a>. In future updates, if we identify sufficient trials, we will conduct sensitivity analyses excluding: </p> <p> <ol id="CD010298-list-0017"> <li> <p>Trials at high risk of bias (i.e., trials that do not meet at least one of the criteria for assessing risk of bias as outlined earlier). We will not remove trials at high risk of bias from the main analysis but will analyze them separately. </p> </li> <li> <p>Trials with a total attrition of &gt; 30%, or where baseline differences between the groups exceed 10%, or both. </p> </li> <li> <p>Unpublished studies, since these may not have been subjected to the peer review process and may have intrinsic bias issues. </p> </li> </ol> </p> <section id="CD010298-sec-0057"> <h5 class="title">Trial sequential analysis</h5> <p>If a sufficient number of trials had met the inclusion criteria we would also have conducted a trial sequential analysis, which is a methodology that combines an information size calculation (cumulated sample sizes of included trials) for meta‐analysis with the threshold of statistical significance. Trial sequential analysis is a tool for quantifying the statistical reliability of data in a cumulative meta‐analysis adjusting P values for repetitive testing on accumulating data (<a href="./references#CD010298-bbs2-0029" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD010298-bbs2-0112" title="PogueJM , YusufS . Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials1997;18(6):580‐93, 661‐6. [PUBMED: 9408720] ">Pogue 1997</a>; <a href="./references#CD010298-bbs2-0113" title="PogueJ , YusufS . Overcoming the limitations of current meta‐analysis of randomised controlled trials. Lancet1998;351(9095):47‐52. [PUBMED: 9433436] ">Pogue 1998</a>; <a href="./references#CD010298-bbs2-0139" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [PUBMED: 18824467] ">Thorlund 2009</a>; <a href="./references#CD010298-bbs2-0145" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>Meta‐analysis may result in type I errors due to sparse data or due to repeated significance testing when updating meta‐analysis with new trials (<a href="./references#CD010298-bbs2-0029" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD010298-bbs2-0073" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random‐effects meta‐analysis. Statistics in Medicine2011;30(9):903‐21. [PUBMED: 21472757] ">Higgins 2011e</a>; <a href="./references#CD010298-bbs2-0145" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). In a single trial, interim analysis increases the risk of type I errors. To avoid type I errors, group sequential monitoring boundaries are applied to decide whether a trial could be terminated early because of a sufficiently small P value that is the cumulative Z‐curve crosses the monitoring boundaries (<a href="./references#CD010298-bbs2-0082" title="LanGKK , DemetsDL . Discrete sequential boundaries for clinical trials. Biometrika1983;70(3):659‐63. ">Lan 1983</a>). Sequential monitoring boundaries can be applied to meta‐analysis as well, called trial sequential monitoring boundaries (<a href="./references#CD010298-bbs2-0145" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). In trial sequential analysis, the addition of each trial in a cumulative meta‐analysis is regarded as an interim meta‐analysis and helps to clarify whether additional trials are needed. </p> <p>The idea in trial sequential analysis is that if the cumulative Z‐curve crosses the boundary, a sufficient level of evidence is reached and no further trials may be needed. If the Z‐curve does not cross the boundary then there is insufficient evidence to reach a conclusion. To construct the trial sequential monitoring boundaries the required information size is needed and is calculated as the least number of participants needed in a well‐powered single trial (<a href="./references#CD010298-bbs2-0029" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD010298-bbs2-0112" title="PogueJM , YusufS . Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials1997;18(6):580‐93, 661‐6. [PUBMED: 9408720] ">Pogue 1997</a>; <a href="./references#CD010298-bbs2-0113" title="PogueJ , YusufS . Overcoming the limitations of current meta‐analysis of randomised controlled trials. Lancet1998;351(9095):47‐52. [PUBMED: 9433436] ">Pogue 1998</a>; <a href="./references#CD010298-bbs2-0145" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). We would applied trial sequential analysis since it prevents an increase of the risk of type I error (&lt; 5%) due to potential multiple updating in a cumulative meta‐analysis and provides us with important information in order to estimate the level of evidence of the experimental intervention. Additionally, trial sequential analysis provides us with important information regarding the need for additional trials and the required sample size of such trials. </p> <p>We would have applied trial sequential monitoring boundaries according to a heterogeneity‐adjusted required information size based on an a priori 10% relative risk reduction employing α = 0.05 and ß = 0.20. </p> <p>We would have conducted trial sequential analysis using available statistical software (<a href="./references#CD010298-bbs2-0039" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Version http://ctu.dk/tsa/ (accessed 29 September 2011). Copenhagen: Central Trial Unit, 2011. ">CTU 2011</a>; <a href="./references#CD010298-bbs2-0140" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). 2011. http://ctu.dk/tsa/files/tsa_manual.pdf (accessed 30 April 2012). ">Thorlund 2011a</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010298-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010298-sec-0058"></div> <section id="CD010298-sec-0059"> <h3 class="title">Description of studies</h3> <section id="CD010298-sec-0060"> <h4 class="title">Results of the search</h4> <p>We identified 1175 references using the previously described strategy. Two trials (26 publications) with a total of 528 participants met our inclusion criteria (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). <a href="#CD010298-fig-0001">Figure 1</a> shows the flowchart results of the study selection as a Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement (<a href="./references#CD010298-bbs2-0097" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. [PUBMED: 19631508] ">Moher 2009</a>). </p> <div class="figure" id="CD010298-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010298-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010298-sec-0061"> <h4 class="title">Included studies</h4> <section id="CD010298-sec-0062"> <h5 class="title">Interventions and populations assessed in the trials</h5> <p>One trial compared ruxolitinib with placebo (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>) and the other compared ruxolitinib with best available therapy (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). Both trials initiated ruxolitinib following an oral schema of administration (15 mg twice daily or 20 mg twice daily), based on baseline peripheral blood platelet count. We did not identify trials comparing JAK inhibitors head to head. </p> <p>Best available therapy was composed any commercially available as monotherapy or in combination such as: antineoplastic agents, glucocorticoids, anti‐anemia preparations, immunomodulatory agents, purine analogs, antigonadotropins and similar agents, interferons, nitrogen mustard analogs, pyrimidine analogs, or no therapy at all and which could be changed during the treatment phase (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> <p><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> and <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> included patients diagnosed with PMF, post‐polycythemia vera‐MF or post‐essential thrombocythemia‐MF according to the 2008 WHO criteria. The mean percentage of male participants was 56% (± 2.83), with a median age of 68 years. </p> </section> <section id="CD010298-sec-0063"> <h5 class="title">Location and timing of trials</h5> <p>Both trials were published in 2012 and were conducted in USA, Canada, Australia (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>), and several European countries (Austria, Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, and UK) (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> </section> <section id="CD010298-sec-0064"> <h5 class="title">Trial methods</h5> <p>The two trials were conducted using a parallel study design. The trials had a sample size of 219 (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>) and 309 (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>) patients. Both trials were conducted with a priori sample size estimation and the follow‐ups ranged from 32 to 61 weeks (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> <p>We have given a detailed description of the trials in the <a href="./references#CD010298-sec-0149" title="">Characteristics of included studies</a> tables (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> </section> </section> <section id="CD010298-sec-0065"> <h4 class="title">Excluded studies</h4> <p>We excluded 13 studies (<a href="./references#CD010298-bbs2-0003" title="GeyerH , CannonK , KnightE , FaubleV , CamorianoJ , EmanuelR , et al. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Leukemia &amp; Lymphoma2014;55(1):195‐7. [PUBMED: 23647081] VerstovsekS . Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. Leukemia &amp; Lymphoma2014;55(1):5‐6. [PUBMED: 23829281] ">Geyer 2014</a>; <a href="./references#CD010298-bbs2-0004" title="GisslingerH , McMullinMF , JaekelN , MillerCB , VerstovsekS , HarrisonCN , et al. A phase Ib, open‐label, dose‐finding study of ruxolitinib in patients (pts) with primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF), or post‐essential thrombocythemia‐myelofibrosis (PET‐MF) and baseline platelets (PLTs) 50 to &lt;100 x 109/l. Journal of Clinical Oncology2012;30(15 Suppl):TPS6642. ">Gisslinger 2012</a>; <a href="./references#CD010298-bbs2-0005" title="GuglielmelliP , BarosiG , RambaldiA , MarchioliR , MasciulliA , TozziL , et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood2011;118(8):2069‐76. [PUBMED: 21725052] ">Guglielmelli 2011</a>; <a href="./references#CD010298-bbs2-0006" title="leCoutrePD , GisslingerH , ZacheeP , GuptaV , PerezJR , SchenkN , et al. An open‐label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post‐polycythemia myelofibrosis (PPV MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). Journal of Clinical Oncology2012;30(15 Suppl):TPS6640. ">le Coutre 2012</a>; <a href="./references#CD010298-bbs2-0007" title="MesaRA , CamorianoJK , GeyerSM , WuW , KaufmannSH , RiveraCE , et al. A phase II trial of tipifarnib in myelofibrosis: primary, post‐polycythemia vera and post‐essential thrombocythemia. Leukemia2007;21(9):1964‐70. [PUBMED: 17581608] ">Mesa 2007</a>; <a href="./references#CD010298-bbs2-0008" title="MesaRA , KiladjianJJ , VerstovsekS , Al‐AliHK , GotlibJ , GisslingerH , et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica2014;99(2):292‐8. [PUBMED: 23911705] ">Mesa 2014</a>; <a href="./references#CD010298-bbs2-0009" title="PardananiA , GotlibJR , JamiesonC , CortesJE , TalpazM , StoneRM , et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Journal of Clinical Oncology2011;29(7):789‐96. [PUBMED: 21220608] PardananiAD , GotlibJ , JamiesonC , CortesJ , TalpazM , StoneRM , et al. A phase I study of TG101348, an orally bioavailable JAK2‐selective inhibitor, in patients with myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood (ASH Annual Meeting Abstracts). 2009; Vol. 112: 755. ">Pardanani 2011a</a>; <a href="./references#CD010298-bbs2-0010" title="PardananiA , LabordeRR , LashoTL , FinkeC , BegnaK , Al‐KaliA , et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia2013;27(6):1322‐7. [PUBMED: 23459451] ">Pardanani 2013</a>; <a href="./references#CD010298-bbs2-0011" title="SantosFPS , KantarjianHM , JainN , ManshouriT , ThomasDA , Garcia‐ManeroG , et al. Phase 2 study of CEP‐701, an orally available JAK2 inhibitor, in patients with primary or post‐polycythemia vera/essential thrombocythemia myelofibrosis. Blood2010;115(6):1131‐6. [PUBMED: 20008298] ">Santos 2010</a>; <a href="./references#CD010298-bbs2-0012" title="TalpazM , HamburgSI , JamiesonK , TerebeloHR , AfrinL , WintonEF , et al. Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100x109/L. Journal of Clinical Oncology2012;30(15 Suppl):TPS6630. TalpazM , PaquetteR , AfrinL , HamburgSI , PrchalJT , JamiesonK , et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. Journal of Hematology &amp; Oncology2013;6(1):81. [24283202] ">Talpaz 2013</a>; <a href="./references#CD010298-bbs2-0013" title="VerstovsekS , KantarjianH , MesaRA , PardananiAD , Cortes‐FrancoJ , ThomasDA , et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New England Journal of Medicine2010;363(12):1117‐27. [PUBMED: 20843246] ">Verstovsek 2010</a>; <a href="./references#CD010298-bbs2-0014" title="VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 793. ">Verstovsek 2011</a>; <a href="./references#CD010298-bbs2-0015" title="VerstovsekS , TamCS , WadleighM , SokolL , SmithCC , BuiLA , et al. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leukemia Research2014;38(3):316‐22. [PUBMED: 24374145] ">Verstovsek 2014</a>). The excluded studies were non‐RCTs (see <a href="./references#CD010298-sec-0150" title="">Characteristics of excluded studies</a> for details). </p> <section id="CD010298-sec-0066"> <h5 class="title">Ongoing trials</h5> <p>We identified one ongoing trial (<a href="./references#CD010298-bbs2-0016" title="PardananiAD , CortesJE , CervantesF , HarrisonCN , PassamontiF , LebedinskyC , et al. JAKARTA: A phase III, multicenter, randomized, double‐blind, placebo‐controlled, three‐arm study of SAR302503 in patients with intermediate‐2 or high‐risk primary myelofibrosis (MF), post‐polycythemia vera (PV) MF, or post‐essential thrombocythemia (ET) MF with splenomegaly. Journal of Clinical Oncology2012;30(15 Suppl):TPS6639. ">NCT01437787</a>) entitled "Phase III study of SAR302503 in intermediate‐2 and high risk patients with myelofibrosis (JAKARTA)". It is a phase 3, multicenter, randomized, double‐blind, placebo‐controlled, three‐arm study of SAR302503 in patients with intermediate‐2 or high‐risk PMF, post‐polycythemia vera MF, or post‐essential thrombocythemia MF with splenomegaly. This RCT will assess the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared with placebo in the reduction of spleen volume. </p> </section> </section> </section> <section id="CD010298-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>We have summarized the risks of bias in the included trials in <a href="#CD010298-fig-0002">Figure 2</a> and <a href="#CD010298-fig-0003">Figure 3</a>, and are detailed in the <a href="./references#CD010298-sec-0149" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD010298-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010298-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010298-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010298-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010298-sec-0068"> <h4 class="title">Allocation</h4> <section id="CD010298-sec-0069"> <h5 class="title">Random sequence generation</h5> <p>Both trials randomized participants by an interactive voice response system. The risk of bias arising from the method of generation of the allocation sequence was low in both trials (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> </section> <section id="CD010298-sec-0070"> <h5 class="title">Allocation concealment</h5> <p>Both trials randomized participants by an interactive voice response system. The risk of bias arising from the method of allocation concealment was low in both trials (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> </section> </section> <section id="CD010298-sec-0071"> <h4 class="title">Blinding</h4> <p>Drug preparations in <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> were prepared to be indistinguishable, thus avoiding risk of performance or detection bias. On the other hand, <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> had a open design and had a high risk of performance or detection bias for most of the outcomes assessed. </p> <section id="CD010298-sec-0072"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <section id="CD010298-sec-0073"> <h6 class="title">1. Primary outcomes</h6> <section id="CD010298-sec-0074"> <p><b>Overall survival</b></p> <p>We judged the risk of bias as low in this domain in both the trials (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> </section> <section id="CD010298-sec-0075"> <p><b>Progression‐free survival</b></p> <p>The risk of bias of this domain was judged as low in <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>. We rated the <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> trial as at high risk of bias because it is an open trial. </p> </section> <section id="CD010298-sec-0076"> <p><b>Safety</b></p> <p>We reported <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> as at low risk of bias for safety outcomes. <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> was at high risk of bias. </p> </section> </section> <section id="CD010298-sec-0077"> <h6 class="title">2. Secondary outcomes</h6> <section id="CD010298-sec-0078"> <p><b>Health‐related quality of life</b></p> <p>We reported a low risk of bias in this outcome in <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>. However, the risk of bias was high in <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> because it is an open trial. </p> </section> <section id="CD010298-sec-0079"> <p><b>Leukemia‐free survival</b></p> <p>One trial did not assess this end point, therefore we judged it as at unclear risk of bias (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>). The other trial (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>) was at high risk of bias. </p> </section> <section id="CD010298-sec-0080"> <p><b>Reduction in spleen size</b></p> <p>We judged the quality of <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> as at low risk of bias. However, <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> was at high risk of bias. </p> </section> <section id="CD010298-sec-0081"> <p><b>Anemia response</b></p> <p>We reported the quality of the included trials (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>) as at unclear risk of bias. </p> </section> </section> </section> </section> <section id="CD010298-sec-0082"> <h4 class="title">Incomplete outcome data</h4> <p>We judged a high risk of bias for <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> due to reporting of the primary outcome (reduction in spleen size) using only 79.2% (245/309) of the initially randomized participants (ruxolitinib group (89.6% (139/155)) versus placebo group (68.8% (106/154)). Furthermore, this trial shows an imbalance of 20.8% between the comparison groups. We considered <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> as at low risk of bias. </p> </section> <section id="CD010298-sec-0083"> <h4 class="title">Selective reporting</h4> <p>Both trials were at low risk of reporting bias (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> </section> <section id="CD010298-sec-0084"> <h4 class="title">Other potential sources of bias</h4> <p>A pharmaceutical company funded <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> and <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>. Therefore, we rated both trials at high risk of industry bias (<a href="./references#CD010298-bbs2-0086" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>). </p> </section> </section> <section id="CD010298-sec-0085"> <h3 class="title" id="CD010298-sec-0085">Effects of interventions</h3> <p>See: <a href="./full#CD010298-tbl-0001"><b>Summary of findings for the main comparison</b> Ruxolitinib compared with placebo for treating myelofibrosis</a>; <a href="./full#CD010298-tbl-0002"><b>Summary of findings 2</b> Ruxolitinib compared with best available therapy for treating myelofibrosis</a> </p> <p>The results of this Cochrane review are based on two included trials (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). See <a href="./full#CD010298-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD010298-tbl-0002">summary of findings Table 2</a> for evidence reported by the trials on outcomes. </p> <section id="CD010298-sec-0086"> <h4 class="title">1. Primary outcomes</h4> <section id="CD010298-sec-0087"> <h5 class="title">Overall survival</h5> <section id="CD010298-sec-0088"> <h6 class="title">Ruxolitinib versus placebo</h6> <p>Ruxolitinib significantly improved overall survival at 51 weeks of follow‐up, when compared with placebo (HR 0.51, 95% CI 0.27 to 0.98; one trial, 309 participants, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD010298-sec-0089"> <h6 class="title">Ruxolitinib versus best available therapy</h6> <p>There was no significant difference between ruxolitinib and best available therapy in overall survival at 48 weeks of follow‐up (HR 0.70; 95% CI 0.20 to 2.47; one trial, 219 participants; P = 0.58, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0011" title="">Analysis 2.1</a>). </p> </section> </section> <section id="CD010298-sec-0090"> <h5 class="title">Progression‐free survival</h5> <section id="CD010298-sec-0091"> <h6 class="title">Ruxolitinib versus placebo</h6> <p><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> did not report results on progression‐free survival. </p> </section> <section id="CD010298-sec-0092"> <h6 class="title">Ruxolitinib versus best available therapy</h6> <p>The comparison between ruxolitinib and best available therapy showed no statistically significant difference in progression‐free survival at 48 weeks of follow‐up (HR 0.81, 95% CI 0.47 to 1.39; P = 0.45, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0012" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD010298-sec-0093"> <h5 class="title">Safety</h5> <p>We report data on adverse events (grades 3 or 4 according to the National Cancer Institute Common Terminology Criteria for Adverse Events) observed in 10% or more of patients who received ruxolitinib. </p> <section id="CD010298-sec-0094"> <h6 class="title">Ruxolitinib versus placebo</h6> <section id="CD010298-sec-0095"> <p><b>Hematological adverse events</b></p> <p>Ruxolitinib compared with placebo showed a statistically significant increase in risk of anemia (70/155 (45.16%) versus 29/151 (19.20%); RR 2.35, 95% CI 1.62 to 3.41, <i>low quality evidence</i> ), thrombocytopenia (20/155 (12.90%) versus 2/151 (1.32%); RR 9.74, 95% CI 2.32 to 40.96, <i>low quality evidence</i> ), and neutropenia (11/155 (7.09%) versus 3/151 (1.98%); RR 3.57; 95% CI 1.02 to 12.55, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD010298-sec-0096"> <p><b>Non‐hematological adverse events</b></p> <p>Patients treated with ruxolitinib, compared with placebo, had a statistically significant reduction in abdominal pain (4/155 (2.58%) versus 17/151 (11.25%); RR 0.23, 95% CI 0.08 to 0.67, <i>low quality evidence</i> ), and dizziness (1/155 (0.64%) versus 10/151 (6.62%); RR 0.10, 95% CI 0.01 to 0.75, <i>low quality evidence</i>). </p> <p>Comparing ruxolitinib with placebo, there was not a statistically significant difference in terms of fatigue (8/155 (5.16%) versus 10/151 (6.62%); RR 0.78, 95% CI 0.32 to 1.92; P = 0.59, <i>low quality evidence</i> ), dyspnea (2/155 (1.29%) versus 10/151 (6.62%); RR 0.32, 95% CI 0.07 to 1.58; P = 0.16, <i>low quality evidence</i> ), arthralgia (3/155 (1.93%) versus 1/151 (0.66%); RR 2.92, 95% CI 0.31 to 27.79; P = 0.35, <i>low quality evidence</i> ), nausea (0/155 (0%) versus 1/151 (0.66%); RR 0.32, 95% CI 0.01 to 7.91; P = 0.49, <i>low quality evidence</i> ), vomiting (1/155 (0.64%) versus 1/151 (0.66%); RR 0.97, 95% CI 0.06 to 15.43; P = 0.99, <i>low quality evidence</i> ), diarrhea (2/155 (1.29%) versus 0/151 (0%); RR 4.87, 95% CI 0.24 to 100.64; P = 0.39, <i>low quality evidence</i> ), pain in extremity (2/155 (1.29%) versus 0/151 (0%); RR 4.87, 95% CI 0.24 to 100.64; P = 0.31, <i>low quality evidence</i> ), or pyrexia (1/155 (0.64%) versus 1/151 (0.66%); RR 0.97; 95% CI 0.06 to 15.43; P = 0.99, <i>low quality evidence</i>) (see <a href="./references#CD010298-fig-0006" title="">Analysis 1.3</a>). </p> <p><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> did not provide details on adverse drug reactions. </p> </section> </section> <section id="CD010298-sec-0097"> <h6 class="title">Ruxolitinib versus best available therapy</h6> <section id="CD010298-sec-0098"> <p><b>Hematological adverse events</b></p> <p>Comparing ruxolitinib versus best available therapy, there was not a statistically significantly difference in terms of anemia (62/146 (4.10%) versus 23/73 (31.50%); RR 1.35, 95% CI 0.91 to 1.99; P = 0.13, <i>low quality evidence</i> ) and thrombocytopenia (12/146 (8.21%) versus 5/73 (6.84%); RR 1.20, 95% CI 0.44 to 3.28; P = 0.72, <i>low quality evidence</i>) (<a href="./references#CD010298-fig-0013" title="">Analysis 2.3</a>). </p> <p><a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> did not report results regarding neutropenia. </p> </section> <section id="CD010298-sec-0099"> <p><b>Non‐hematological adverse events</b></p> <p>Ruxolitinib compared with best available therapy showed no statistically significant difference in terms of abdominal pain (5/146 (3.42%) versus 2/73 (2.73%); RR 1.25, 95% CI 0.25 to 6.29; P = 0.80, <i>low quality evidence</i> ), fatigue (1/146 (0.68%) versus 0/73 (0%); RR 1.51, 95% CI 0.06 to 36.62; P = 0.80, <i>low quality evidence</i> ), dyspnea (1/146 (0.68%) versus 3/73 (4.10%); RR 0.17, 95% CI 0.02 to 1.57; P = 0.12, <i>low quality evidence</i> ), arthralgia (1/146 (0.68%) versus 0/73 (0%); RR 1.51, 95% CI 0.06 to 36.62; P = 0.80, <i>low quality evidence</i> ), nausea (1/146 (0.68%) versus 0/73 (0%); RR 1.51, 95% CI 0.06 to 36.62; P = 0.80, <i>low quality evidence</i> ), diarrhea (2/146 (1.36%) versus 0/73 (0%); RR 2.52, 95% CI 0.12 to 51.76; P = 0.55, <i>low quality evidence</i> ), pain in extremity (1/146 (0.68%) versus 0/73 (0%); RR 1.51, 95% CI 0.06 to 36.62; P = 0.80, <i>low quality evidence</i> ), pyrexia (3/146 (2.05%) versus 0/73 (0%); RR 3.52, 95% CI 0.18 to 67.32; P = 0.40, <i>low quality evidence</i> ), and headache (2/146 (1.36%) versus 0/73 (0%); RR 2.52, 95% CI 0.12 to 51.76; P = 0.55, <i>low quality evidence</i>) (<a href="./references#CD010298-fig-0014" title="">Analysis 2.4</a>). </p> <p><a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> did not provide details on adverse drug reactions. </p> </section> </section> </section> </section> <section id="CD010298-sec-0100"> <h4 class="title">2. Secondary outcomes</h4> <section id="CD010298-sec-0101"> <h5 class="title">Health‐related quality of life</h5> <section id="CD010298-sec-0102"> <h6 class="title">Ruxolitinib versus placebo</h6> <p><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> assessed health‐related quality of life using the modified symptom score MFSAF. It measured the symptoms of night sweats, itching, abdominal discomfort, pain under the ribs on the left side, a feeling of fullness (early satiety), muscle or bone pain, and inactivity (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>). Each symptom score ranged from 0 (absent symptoms) to 10 (worst imaginable symptoms). The total MFSAF score is the sum of the individual scores, excluding inactivity. </p> <p><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> reported a higher proportion of patients receiving ruxolitinib that achieved a reduction of 50% or more in the total MFSAF score (RR 8.82, 95% CI 4.40 to 17.69; one trial, 309 participants; <a href="./references#CD010298-fig-0007" title="">Analysis 1.4</a>). The trial found a statistically significant improvement in score in the ruxolitinib treated group compared with placebo at 24 weeks follow‐up. It reported that patients receiving ruxolitinib had a mean improvement of 46.1% (median 56.2%) while patients receiving placebo had a mean worsening of 41.8% (median 14.6%) (MD ‐87.90; 95% CI ‐139.58 to ‐36.22; one trial, 232 participants; P = 0.0009, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD010298-sec-0103"> <h6 class="title">Ruxolitinib versus best available therapy</h6> <p><a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> used the European Organization for Research and Treatment of Cancer quality of life questionnaire core model, whose scale has a range of 0 a 100. This trial assessed this outcome at 48 weeks follow‐up. It showed a statistically significant difference comparing ruxolitinib with best available therapy (MD 7.60, 95% CI 0.35 to 14.85; one trial, 96 participants; P = 0.04, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0015" title="">Analysis 2.5</a>). </p> </section> </section> <section id="CD010298-sec-0104"> <h5 class="title">Leukemia‐free survival</h5> <section id="CD010298-sec-0105"> <h6 class="title">Ruxolitinib versus placebo</h6> <p><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> showed no statistically significant difference between ruxolitinib and placebo (HR 5.0, 95% CI 0.52 to 48.07; one trial, 309 participants; P = 0.16, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0010" title="">Analysis 1.7</a>), regarding leukemia‐free survival. </p> </section> <section id="CD010298-sec-0106"> <h6 class="title">Ruxolitinib versus best available therapy</h6> <p><a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> found no statistically significant difference comparing ruxolitinib versus best available therapy on leukemia‐free survival (HR 0.65, 95% CI 0.18 to 2.33; one trial, 219 participants; P = 0.51, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0018" title="">Analysis 2.8</a>). </p> </section> </section> <section id="CD010298-sec-0107"> <h5 class="title">Reduction in spleen volume</h5> <p>The primary end point for both included trials was the proportion of patients with at least a reduction of 35% in spleen volume from baseline to the end of follow‐up (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> <section id="CD010298-sec-0108"> <h6 class="title">Ruxolitinib versus placebo</h6> <p>At week 24, patients receiving ruxolitinib, 139 participants, had a mean reduction in spleen volume of 31.6% (median 33%) compared with 106 participants on placebo who had a mean increase of 8.1% (median 8.5%) (P = no reported) (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>). </p> <p>Ruxolitinib treatment significantly increased the proportion of patients with reduction in spleen volume of ≥ 35% as assessed by magnetic resonance imaging (MRI) or computed tomography (CT) (65/155 (41.94%) versus 1/154 (0.65%); RR 64.58, 95% CI 9.08 to 459.56; one trial, 309 participants; P = 0.0001, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD010298-sec-0109"> <h6 class="title">Ruxolitinib versus best available therapy</h6> <p><a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> showed a statistically significant reduction in spleen size in ruxolitinib group compared with best available therapy. This effect was either at 24 weeks (MD ‐31.9, 95% CI ‐53.85 to ‐9.95; one trial, 216 participants; P = 0.004) or 48 weeks of follow‐up (MD ‐37.4; 95% CI ‐65.41 to ‐9.39; P = 0.004; one trial, 216 participants, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0016" title="">Analysis 2.6</a>). </p> <p>Ruxolitinib treatment significantly increased the proportion of patients with reduction in spleen volume of ≥ 35% as assessed by MRI or CT (41/146 (71.92%) versus 0/73 (0%); RR 41.78, 95% CI 2.61 to 669.75; P = 0.008, <i>low quality evidence</i>; <a href="./references#CD010298-fig-0017" title="">Analysis 2.7</a>). </p> </section> </section> <section id="CD010298-sec-0110"> <h5 class="title">Anemia response</h5> <p>No trial assessed this outcome.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010298-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010298-sec-0111"></div> <section id="CD010298-sec-0112"> <h3 class="title" id="CD010298-sec-0112">Summary of main results</h3> <p>We performed a systematic review with the aim of obtaining the core evidence regarding clinical benefits and harms of Janus kinase inhibitors in MF. This Cochrane Review included two small trials with 528 participants. The trials compared ruxolitinib with placebo (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>) and best available therapy (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). Both trials were sponsored by a pharmaceutical company. See <a href="./full#CD010298-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD010298-tbl-0002">summary of findings Table 2</a> for the grading recommendations for each of the variables assessed by both trials. </p> <p>The following findings emerged from this Cochrane Review:</p> <p> <ul id="CD010298-list-0018"> <li> <p>Included trials reported overall survival at 51 weeks (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>) and at 48 weeks (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). The analysis showed a significant improvement in overall survival with ruxolitinib compared with placebo but a non‐significant change compared with best available therapy. </p> </li> <li> <p>One trial assessed progression‐free survival at 48 weeks follow‐up, which was found to be non‐statistically different between ruxolitinib and best available therapy (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> </li> <li> <p>Leukemia‐free survival was reported by <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> and <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> and there was no significant difference between ruxolitinib and placebo or best available therapy treated patients. </p> </li> <li> <p>With respect to the hematological adverse events, the risk of anemia and thrombocytopenia was increased with ruxolitinib compared with placebo (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>), but was similar compared with best available therapy (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> reported neutropenia and analysis showed an increased risk, which is statistically significant in the ruxolitinib group compared with placebo. </p> </li> <li> <p>Compared with placebo, ruxolitinib showed a significant reduction in abdominal pain and dizziness (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>). </p> </li> <li> <p>There was not a statistical significant difference regarding non‐hematological grade 3 to 4 adverse events including fatigue, arthralgia, nausea, diarrhea, extremity pain and pyrexia, between ruxolitinib and placebo or best available therapy (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). Only <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> reported vomiting and showed similar risk in ruxolitinib treated patients compared with placebo. The risk of headache was also not statistically different between ruxolitinib and best available therapy. </p> </li> <li> <p>Analysis of the included trials reported a statistically significant improvement in health‐related quality of life compared with placebo (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>) or with best‐available therapy (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). </p> </li> <li> <p>Improvement in splenomegaly was reported both as dichotomous and continuous approaches. Ruxolitinib reduced the proportion of patients with reduction in spleen volume of ≥ 35% as assessed by MRI or CT compared with placebo or best available therapy at 24 and 48 week of follow‐up. <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> also showed a statistically significant reduction in spleen volume reported as continuous variable, in ruxolitinib group compared with best available therapy. Continuous data of spleen size reduction in <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> trial could not be analyzed because of lack of reporting of the dispersion measures. </p> </li> </ul> </p> </section> <section id="CD010298-sec-0113"> <h3 class="title" id="CD010298-sec-0113">Overall completeness and applicability of evidence</h3> <p>We found weak evidence suggesting that ruxolitinib increases overall survival compared with placebo or best available therapy in patients with MF. However, this conclusion is based on two small RCTs which were sponsored by a drug company (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). Both trials were not powered for finding significant difference in overall survival. Accordingly, both included trials have risk of random error (<a href="./references#CD010298-bbs2-0120" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savović 2012</a>; <a href="./references#CD010298-bbs2-0141" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis‐‐a simulation study. PLoS One2011;6(10):e25491. [PUBMED: 22028777] ">Thorlund 2011b</a>). </p> <p>The results in this Cochrane Review are based on data from two trials that included a broad range of patients with both primary and secondary MF who received different treatment approaches. Although these aspects could be considered as a threat to applicability, the consistency in the results derived from our analyses shows that the included trials may represent a broad picture of patients with MF. We tried to identify all the published and unpublished data, and ongoing studies to warrant confidence in the completeness of the data gathered in the review. However, we cannot rule out that the calculated effects are overestimated due to potential industry bias, unblinding for assessing health‐related quality of life in one included trial (<a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>), and small sample size of the included clinical trials. Furthermore, we do not preclude an underestimation of safety findings (<a href="./references#CD010298-bbs2-0120" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savović 2012</a>; <a href="./references#CD010298-bbs2-0141" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis‐‐a simulation study. PLoS One2011;6(10):e25491. [PUBMED: 22028777] ">Thorlund 2011b</a>; <a href="./references#CD010298-bbs2-0146" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. [PUBMED: 18316340] ">Wood 2008</a>). <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> did not report data on neutropenia which prevented analysis for this relevant adverse event on comparison with best available therapy. </p> <p>In terms of overall survival, the duration of follow‐up in <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> and <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> was 51 weeks and 48 weeks, respectively. Both periods were very short regarding the reported median overall survival of MF: 11.3 years for low risk, 7.9 years for intermediate‐1 risk, 4.0 years for intermediate‐2 risk, and 2.3 years for high‐risk MF (<a href="./references#CD010298-bbs2-0033" title="CervantesF , DupriezB , PereiraA , PassamontiF , ReillyJT , MorraE , et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood2009;113(13):2895‐901. [PUBMED: 18988864] ">Cervantes 2009</a>). </p> <p>When dealing with such neutral results, we need to keep in mind that 'absence of evidence' is not 'evidence of absence' (<a href="./references#CD010298-bbs2-0018" title="AltmanDG , BlandJM . Absence of evidence is not evidence of absence. BMJ1995;311(7003):486. [PUBMED: 7647644] ">Altman 1995</a>; <a href="./references#CD010298-bbs2-0048" title="Fermi Paradox. www.crystalinks.com/fermiparadox.html (accessed 12 April 2013). ">Fermi Paradox</a>). The fact that this review did not detect strong differences between comparison groups does not imply that placebo or best available therapy and ruxolitinib have the same overall survival risk. The first possible explanation is failure to determine an appropriate sample size (<a href="./references#CD010298-bbs2-0055" title="GreenSB . Design of randomized trials. Epidemiologic Reviews2002;24(1):4‐11. [PUBMED: 12119855] ">Green 2002</a>; <a href="./references#CD010298-bbs2-0123" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [PUBMED: 7823387] ">Schulz 1995</a>). </p> <p>Furthermore, we would like to point out a form of bias known as dichotomization. Dichotomization is the transformation of a continuous outcome (response) to a binary outcome (<a href="./references#CD010298-bbs2-0047" title="FedorovV , ManninoF , ZhangR . Consequences of dichotomization. Pharmaceutical Statistics2009;8(1):50‐61. [PUBMED: 18389492] ">Fedorov 2009</a>). There are several publications reporting the negative consequences when a continuous variable is dichotomized i.e., loss of information which leads to loss of power or conversely a sample size increase to maintain power (<a href="./references#CD010298-bbs2-0019" title="AltmanDG , RoystonP . The cost of dichotomising continuous variables. BMJ2006;332(7549):1080. [PUBMED: 16675816] ">Altman 2006</a>; <a href="./references#CD010298-bbs2-0047" title="FedorovV , ManninoF , ZhangR . Consequences of dichotomization. Pharmaceutical Statistics2009;8(1):50‐61. [PUBMED: 18389492] ">Fedorov 2009</a>; <a href="./references#CD010298-bbs2-0087" title="MacCallumRC , ZhangS , PreacherKJ , RuckerDD . On the practice of dichotomization of quantitative variables. Psychological Methods2002;7(1):19‐40. ">MacCallum 2002</a>). Power is reduced and relationships may be obscured or changed (<a href="./references#CD010298-bbs2-0110" title="PeacockJL , SauzetO , EwingsSM , KerrySM . Dichotomising continuous data while retaining statistical power using a distributional approach. Statistics in Medicine2012;31(26):3089‐103. [PUBMED: 22865598] ">Peacock 2012</a>). However, not only are differences in means difficult for clinicians to interpret, but thresholds also occur in many areas of medical practice and cannot be ignored (<a href="./references#CD010298-bbs2-0110" title="PeacockJL , SauzetO , EwingsSM , KerrySM . Dichotomising continuous data while retaining statistical power using a distributional approach. Statistics in Medicine2012;31(26):3089‐103. [PUBMED: 22865598] ">Peacock 2012</a>). Dichotomization may also increase the risk of a positive result being a false positive (<a href="./references#CD010298-bbs2-0019" title="AltmanDG , RoystonP . The cost of dichotomising continuous variables. BMJ2006;332(7549):1080. [PUBMED: 16675816] ">Altman 2006</a>; <a href="./references#CD010298-bbs2-0020" title="AustinPC , BrunnerLJ . Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Statistics in Medicine2004;23(7):1159‐78. [PUBMED: 15057884] ">Austin 2004</a>). Therefore, it has been strongly recommended to avoid, as much as possible, the categorization of variables when doing analyses (<a href="./references#CD010298-bbs2-0019" title="AltmanDG , RoystonP . The cost of dichotomising continuous variables. BMJ2006;332(7549):1080. [PUBMED: 16675816] ">Altman 2006</a>; <a href="./references#CD010298-bbs2-0040" title="CumsilleF , BangdiwalaSI . [Categorizing variables in the statistical analysis of data: consequences for interpreting the results] [Categorización de variables en el análisis estadístico de datos: consecuencias sobre la interpretación de resultados]. Revista Panamericana de Salud Pública2000;8(5):348‐54. [PUBMED: 11190972] ">Cumsille 2000</a>; <a href="./references#CD010298-bbs2-0087" title="MacCallumRC , ZhangS , PreacherKJ , RuckerDD . On the practice of dichotomization of quantitative variables. Psychological Methods2002;7(1):19‐40. ">MacCallum 2002</a>; <a href="./references#CD010298-bbs2-0128" title="StreinerDL . Breaking up is hard to do: The heartbreak of dichotomizing continuous data. Canadian Journal of Psychiatry2002;47( 3 ):262‐6. ">Streiner 2002</a>). In this Cochrane Review we identified dichotomization in both trials for measuring the clinical benefit of ruxolitinib compared with control on the main outcome of these trials, spleen size reduction (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). Both trials assessed the clinical benefit of ruxolitinib on the basis of spleen size measurements and on the basis of the proportions of patients with spleen size reduction in prespecified range (≥ 35%). Also, <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> reported only mean and median of spleen size without any data of standard deviation, standard error, 95% CI, and interquartile range, respectively. In consequence, the true precision of the clinical benefit of ruxolitinib compared with placebo on reduction in spleen size is unknown. </p> <p><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> and <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> used a surrogate outcome for assessing a benefit effect of the ruxolitinib on MF. This review could adapt the comments and points of view from <a href="./references#CD010298-bbs2-0147" title="YudkinJS , LipskaKJ , MontoriVM . The idolatry of the surrogate. BMJ2011;343:d7995. [PUBMED: 22205706] ">Yudkin 2011</a> and ratified by <a href="./references#CD010298-bbs2-0052" title="GodleeF . Outcomes that matter to patients. BMJ2012;344:e318. [DOI: http://dx.doi.org/10.1136/bmj.e318] ">Godlee 2012</a> which are related with diabetes world. From their perspective within the world of malignant hematological disorder we would warn that surrogates like spleen size or spleen volume could show much larger responses to treatment than "hard" outcomes that matter to patients, such as overall survival, progression‐free survival impairment or quality of life. Furthermore, surrogate outcomes also respond sooner, which makes them popular with drug companies and others doing clinical trials. Moreover, these "hard" end points generally show much smaller responses to interventions than surrogate markers. As it has happened with other medical disorders, to adopt ruxolitinib for treating patients with MF may be based on artificially inflated expectations. Outcome events that are more frequent in occurrence and more proximate in time, compared with customary disease‐specific mortality or incidence outcomes, could give answers that are based on smaller trials of shorter duration (<a href="./references#CD010298-bbs2-0115" title="PrenticeRL . Surrogate and mediating endpoints: current status and future directions. Journal of the National Cancer Institute2009;101(4):216‐7. [PUBMED: 19211455] ">Prentice 2009</a>). </p> <p>Summing up, the clinical meaning of spleen size reduction in prespecified range that is ≥ 35%, is unknown. It can be suggested to adopt ≥ 50% as the cut‐off, on the basis of the international response criteria of a reduction of 50% or more in spleen length as assessed by palpation. Since spleen size reduction was the primary outcome used by <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> and <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> for assessing efficacy of ruxolitinib, from our point of view it would have been more relevant to show the spleen size reduction using continuous measure rather than as binary data, with all dispersion measures. </p> </section> <section id="CD010298-sec-0114"> <h3 class="title" id="CD010298-sec-0114">Quality of the evidence</h3> <p>We did not grade any the results as high quality evidence primarily because of small sample sizes and the high risk of bias due to a lack of blinding and high attrition (<a href="./full#CD010298-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010298-tbl-0002">summary of findings Table 2</a>). </p> <p>We found many sources of bias in both included trials (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>; <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>). First, we detected performance bias in <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>. Second, there was suspicion of detection bias regarding progression‐free survival in <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>. Third, <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> was described as open trial, therefore it had a high risk of detection bias (blinding of outcome assessor) regarding health‐related quality of life and reduction in spleen size. Fourth, <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> showed a high risk of attrition bias (<a href="./references#CD010298-bbs2-0114" title="PortaM . A Dictionary of Epidemiology. 5th Edition. New York: Oxford University Press, 2008. ">Porta 2008</a>). Fifth, dichotomization increases the risk of a positive result being a false positive (<a href="./references#CD010298-bbs2-0019" title="AltmanDG , RoystonP . The cost of dichotomising continuous variables. BMJ2006;332(7549):1080. [PUBMED: 16675816] ">Altman 2006</a>; <a href="./references#CD010298-bbs2-0020" title="AustinPC , BrunnerLJ . Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Statistics in Medicine2004;23(7):1159‐78. [PUBMED: 15057884] ">Austin 2004</a>). Sixth, a pharmaceutical company sponsored both trials and are potentially at high risk of industry bias. Significant evidence supports a clear association between pharmaceutical industry funding of clinical trials and pro‐industry results (<a href="./references#CD010298-bbs2-0017" title="Als‐NielsenB , ChenW , GluudC , KjaergardLL . Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA2003;290(7):921‐8. [PUBMED: 12928469] ">Als‐Nielsen 2003</a>; <a href="./references#CD010298-bbs2-0043" title="DjulbegovicB , KumarA , MiladinovicB , ReljicT , GalebS , MhaskarA , et al. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. PLoS One2013;8(3):e58711. [PUBMED: 23555593] ">Djulbegovic 2013</a>; <a href="./references#CD010298-bbs2-0045" title="DoucetM , SismondoS . Evaluating solutions to sponsorship bias. Journal of Medical Ethics2008;34(8):627‐30. [PUBMED: 18667655] ">Doucet 2008</a>; <a href="./references#CD010298-bbs2-0053" title="GolderS , LokeYK . Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry‐funded studies?. British Journal of Clinical Pharmacology2008;66(6):767‐73. [PUBMED: 18754841] ">Golder 2008</a>; <a href="./references#CD010298-bbs2-0080" title="JørgensenAW , MaricKL , TendalB , FaurschouA , GøtzschePC . Industry‐supported meta‐analyses compared with meta‐analyses with non‐profit or no support: differences in methodological quality and conclusions. BMC Medical Research Methodology2008;8:60. [PUBMED: 18782430] ">Jørgensen 2008</a>; <a href="./references#CD010298-bbs2-0085" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ2003;326(7400):1167‐70. [PUBMED: 12775614] ">Lexchin 2003</a>; <a href="./references#CD010298-bbs2-0086" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD010298-bbs2-0121" title="SchottG , PachlH , LimbachU , Gundert‐RemyU , LiebK , LudwigWD . The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Deutsches Arzteblatt International2010;107(17):295‐301. [PUBMED: 20490338] ">Schott 2010a</a>; <a href="./references#CD010298-bbs2-0122" title="SchottG , PachlH , LimbachU , Gundert‐RemyU , LudwigWD , LiebK . The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Deutsches Arzteblatt International2010;107(16):279‐85. [PUBMED: 20467553] ">Schott 2010b</a>). Industry bias results in publication of scientific research which is in favor of the commercial interests of the sponsors. <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> did not report all the data regarding its primary end point, and <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> did not report complete health related quality of life data at 48 weeks follow‐up. Many recommendations have been suggested, such as a public access to trial protocols and results, and more effort should be made to carry out drug trials independently, without the financial support of pharmaceutical companies (<a href="./references#CD010298-bbs2-0121" title="SchottG , PachlH , LimbachU , Gundert‐RemyU , LiebK , LudwigWD . The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Deutsches Arzteblatt International2010;107(17):295‐301. [PUBMED: 20490338] ">Schott 2010a</a>; <a href="./references#CD010298-bbs2-0122" title="SchottG , PachlH , LimbachU , Gundert‐RemyU , LudwigWD , LiebK . The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Deutsches Arzteblatt International2010;107(16):279‐85. [PUBMED: 20467553] ">Schott 2010b</a>). </p> <p><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> and <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> were small trials which are at potential risk of industry bias (<a href="./references#CD010298-bbs2-0142" title="TwomblyR . Small study on industry trial sponsorship leads to big questions about quality and bias. Journal of the National Cancer Institute2007; Vol. 99, issue 13:988‐90. [PUBMED: 17596566] ">Twombly 2007</a>). A small study could cause a small study effect bias (<a href="./references#CD010298-bbs2-0067" title="HemmingK , HuttonJL . Intrapartum amnioinfusion for meconium‐stained amniotic fluid: evidence for small study effect bias?. BJOG2009;116(1):128‐9. [PUBMED: 19087088] ">Hemming 2009</a>). It has been described as "decline effect", by which drugs appear to yield a lower effect size over time (<a href="./references#CD010298-bbs2-0083" title="LauerMS . From hot hands to declining effects: the risks of small numbers. Journal of the American College of Cardiology2012;60(1):72‐4. [PUBMED: 22742403] ">Lauer 2012</a>). The decline effect is due, at least in part, to over interpretation of small studies (<a href="./references#CD010298-bbs2-0083" title="LauerMS . From hot hands to declining effects: the risks of small numbers. Journal of the American College of Cardiology2012;60(1):72‐4. [PUBMED: 22742403] ">Lauer 2012</a>). Therefore, meta‐analyses and systematic reviews should always consider the impact of attrition on baseline imbalances and where possible any baseline imbalances in the analyzed data set and their impact on the outcomes reported (<a href="./references#CD010298-bbs2-0068" title="HewittCE , KumaravelB , DumvilleJC , TorgersonDJ , Trial attrition study group. Assessing the impact of attrition in randomized controlled trials. Journal of Clinical Epidemiology2010;63(11):1264‐70. [PUBMED: 20573482] ">Hewitt 2010</a>). In this Cochrane Review, we found an imbalance between ruxolitinib and placebo of 20.8% and 16.4% regarding spleen size reduction and health‐related quality, respectively (<a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a>). </p> </section> <section id="CD010298-sec-0115"> <h3 class="title" id="CD010298-sec-0115">Potential biases in the review process</h3> <p>In the process for performing a systematic review, there is a group of biases called 'significance‐chasing biases' (<a href="./references#CD010298-bbs2-0079" title="IoannidisJP . The art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>). This group includes publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias (<a href="./references#CD010298-bbs2-0079" title="IoannidisJP . The art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>). </p> <p>Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials as this Cochrane Review. We included two small trials involving 528 patients. However, this Cochrane Review has a low risk of publication bias due to the meticulous trial search. </p> <p>Selective outcome reporting bias operates through suppression of information on specific outcomes and has similarities to publication bias in sense that 'negative' results remain unpublished (<a href="./references#CD010298-bbs2-0079" title="IoannidisJP . The art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>). We found two trials at low risk of selective outcome reporting bias. </p> <p>The major limitation of this review is associated with the small sample size of the included trials. A study with low statistical power has a reduced chance of detecting a true effect (power failure), which overestimates the effect size and low reproducibility of results (<a href="./references#CD010298-bbs2-0030" title="ButtonKS , IoannidisJPA , MokryszC , NosekBA , FlintJ , RobinsonESJ , et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience2013;14(5):365‐76. [DOI: 23571845] ">Button 2013</a>; <a href="./references#CD010298-bbs2-0050" title='FreimanJA , ChalmersTC , SmithHJr , KueblerRR . The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. New England Journal of Medicine1978;299(13):690‐4. [PUBMED: 355881] '>Freiman 1978</a>; <a href="./references#CD010298-bbs2-0081" title="KirbyA , GebskiV , KeechAC . Determining the sample size in a clinical trial. Medical Journal of Australia2002;177(5):256‐7. [PUBMED: 12197821] ">Kirby 2002</a>; <a href="./references#CD010298-bbs2-0096" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. [PUBMED: 9746022] ">Moher 1998</a>). The potential consequences are generation of excess significance, winner's curse, and vibration of effects (<a href="./references#CD010298-bbs2-0077" title="IoannidisJP . Why most published research findings are false. PLoS Medicine2005;2(8):e124. [PUBMED: 16060722] ">Ioannidis 2005</a>; <a href="./references#CD010298-bbs2-0078" title="IoannidisJP . Why most discovered true associations are inflated. Epidemiology2008;19(5):640‐8. [PUBMED: 18633328] ">Ioannidis 2008</a>; <a href="./references#CD010298-bbs2-0111" title="PereiraTV , IoannidisJP . Statistically significant meta‐analyses of clinical trials have modest credibility and inflated effects. Journal of Clinical Epidemiology2011;64(10):1060‐9. [PUBMED: 21454050] ">Pereira 2011</a>). We have provided definitions for excess significance, winner's curse, and vibration of effects definitions in <a href="./appendices#CD010298-sec-0138">Appendix 9</a> (<a href="./references#CD010298-bbs2-0030" title="ButtonKS , IoannidisJPA , MokryszC , NosekBA , FlintJ , RobinsonESJ , et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience2013;14(5):365‐76. [DOI: 23571845] ">Button 2013</a>; <a href="./references#CD010298-bbs2-0078" title="IoannidisJP . Why most discovered true associations are inflated. Epidemiology2008;19(5):640‐8. [PUBMED: 18633328] ">Ioannidis 2008</a>). </p> <p>The main strength of this Cochrane Review is that we have found a need of new powered trials based on main clinical outcomes, such as overall survival and progression‐free survival as primary outcomes. </p> <p>We tried to avoid any bias by having two review authors conduct the steps of study selection, data extraction and analysis, and risk of bias assessment in duplicate with suggestions from other review authors and correspondence with the trial authors when needed. We are not aware of any obvious biases in our review process. </p> <p>Finally, in the 'Summary of findings' tables we present measures of absolute effect for time‐to‐event outcomes (overall survival and progression free survival). In generating such estimates we assumed the control group rate that could be valid for RR estimation as a close approximation to HR. As this approach does not reflect cumulative risk our reported estimate might differ to what would be observed in practice. To our knowledge there is no more robust approaches to this, so the illustrative risk included in the 'Summary of findings' tables should be interpreted with caution. </p> </section> <section id="CD010298-sec-0116"> <h3 class="title" id="CD010298-sec-0116">Agreements and disagreements with other studies or reviews</h3> <p>Although this is the first systematic review on the effects of Janus kinase inhibitors for MF, the results are in concordance with other narrative reviews published to date (<a href="./references#CD010298-bbs2-0089" title="MascarenhasJ , HoffmanR . A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood2013;121(24):4832‐7. [PUBMED: 23570800] ">Mascarenhas 2013</a>; <a href="./references#CD010298-bbs2-0135" title="TefferiA . JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood2012;119(12):2721‐30. [PUBMED: 22279053] ">Tefferi 2012</a>). In general terms these reviews acknowledge the role of ruxolitinib in the control of symptoms and the capacity to reduce splenomegaly, but also highlight the contradictory results regarding other relevant outcomes like survival. Despite the survival benefit observed in the <a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> and the promising results from <a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>, the treatment of MF with ruxolitinib with the intention of prolonging survival would be premature (<a href="./references#CD010298-bbs2-0089" title="MascarenhasJ , HoffmanR . A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood2013;121(24):4832‐7. [PUBMED: 23570800] ">Mascarenhas 2013</a>), especially having in mind that an advantage over best supportive care has still to be shown (<a href="./references#CD010298-bbs2-0135" title="TefferiA . JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood2012;119(12):2721‐30. [PUBMED: 22279053] ">Tefferi 2012</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010298-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010298-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010298-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010298-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ruxolitinib versus placebo, Outcome 1 Overall survival." data-id="CD010298-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ruxolitinib versus placebo, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ruxolitinib versus placebo, Outcome 2 Hematological adverse events (Adverse events observed in 10% or more of patients who received ruxolitinib. Harm (Grades 3 or 4). According to National Cancer Institute Common terminology criteria for adverse events)." data-id="CD010298-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Ruxolitinib versus placebo, Outcome 2 Hematological adverse events (Adverse events observed in 10% or more of patients who received ruxolitinib. Harm (Grades 3 or 4). According to National Cancer Institute Common terminology criteria for adverse events). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ruxolitinib versus placebo, Outcome 3 Non‐hematological adverse events (Adverse events observed in 10% or more of patients who received ruxolitinib. Harm (Grades 3 or 4). According to National Cancer Institute common terminology criteria for adverse events)." data-id="CD010298-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Ruxolitinib versus placebo, Outcome 3 Non‐hematological adverse events (Adverse events observed in 10% or more of patients who received ruxolitinib. Harm (Grades 3 or 4). According to National Cancer Institute common terminology criteria for adverse events). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ruxolitinib versus placebo, Outcome 4 Health‐related quality of life: proportion of patients with a reduction of 50% or more in MFSAF scores at 24 weeks." data-id="CD010298-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Ruxolitinib versus placebo, Outcome 4 Health‐related quality of life: proportion of patients with a reduction of 50% or more in MFSAF scores at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ruxolitinib versus placebo, Outcome 5 Health‐related quality of life: Mean difference in MFSAF at follow‐up scores at 24 weeks." data-id="CD010298-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Ruxolitinib versus placebo, Outcome 5 Health‐related quality of life: Mean difference in MFSAF at follow‐up scores at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ruxolitinib versus placebo, Outcome 6 Reduction in spleen size (≥ 35%) (at 48 weeks follow‐up)." data-id="CD010298-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Ruxolitinib versus placebo, Outcome 6 Reduction in spleen size (≥ 35%) (at 48 weeks follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ruxolitinib versus placebo, Outcome 7 Leukemia‐free survival." data-id="CD010298-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Ruxolitinib versus placebo, Outcome 7 Leukemia‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ruxolitinib versus best available therapy, Outcome 1 Overall survival." data-id="CD010298-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Ruxolitinib versus best available therapy, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ruxolitinib versus best available therapy, Outcome 2 Progression‐free survival (at 48 weeks)." data-id="CD010298-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Ruxolitinib versus best available therapy, Outcome 2 Progression‐free survival (at 48 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ruxolitinib versus best available therapy, Outcome 3 Hematological adverse events." data-id="CD010298-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Ruxolitinib versus best available therapy, Outcome 3 Hematological adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ruxolitinib versus best available therapy, Outcome 4 Non‐hematological adverse events." data-id="CD010298-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Ruxolitinib versus best available therapy, Outcome 4 Non‐hematological adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ruxolitinib versus best available therapy, Outcome 5 Health‐related quality of life." data-id="CD010298-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Ruxolitinib versus best available therapy, Outcome 5 Health‐related quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ruxolitinib versus best available therapy, Outcome 6 Reduction in spleen size." data-id="CD010298-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Ruxolitinib versus best available therapy, Outcome 6 Reduction in spleen size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ruxolitinib versus best available therapy, Outcome 7 Reduction in spleen volume (≥ 35%) (at 24 and 48 weeks follow‐up)." data-id="CD010298-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Ruxolitinib versus best available therapy, Outcome 7 Reduction in spleen volume (≥ 35%) (at 24 and 48 weeks follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010298-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/urn:x-wiley:14651858:media:CD010298:CD010298-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_t/tCD010298-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ruxolitinib versus best available therapy, Outcome 8 Leukemia‐free survival." data-id="CD010298-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Ruxolitinib versus best available therapy, Outcome 8 Leukemia‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/media/CDSR/CD010298/image_n/nCD010298-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010298-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ruxolitinib compared with placebo for treating myelofibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ruxolitinib compared with placebo for treating MF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with treating MF<br/> <b>Settings:</b> Ambulatory<br/> <b>Intervention:</b> Ruxolitinib<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Ruxolitinib</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> <br/> (number of deaths at follow‐up (24 weeks<sup>1</sup>)) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> <br/> (25 to 89)<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.51</b> <br/> (0.27 to 0.98)<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression‐free survival</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not<br/> measured in the included<br/> study </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety (AE, adverse drug reaction): thrombocytopenia</b> <br/> Grades 3 or 4 according to National Cancer Institute<br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> <br/> (31 to 543) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 9.74</b> <br/> (2.32 to 40.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety (AE, adverse drug reaction): neutropenia</b> <br/> Grades 3 or 4 according to National Cancer Institute<br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> <br/> (20 to 249) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.57</b> <br/> (1.02 to 12.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> <br/> Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form<br/> Follow‐up: 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> <br/> (229 to 919) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.82</b> <br/> (4.40 to 17.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in spleen size</b> <br/> Magnetic resonance imaging or computed tomography<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>419 per 1000</b> <br/> (59 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 64.58</b> <br/> (9.08 to 459.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/> (1 trial<sup>5</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is provided in footnote #2. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR:</b> hazard ratio. <b>AE:</b> adverse event; <b>MF:</b> myelofibrosis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> trial established the time of data cut‐off for its main outcome at 24 weeks.<br/> <sup>2</sup>Data obtained from deaths in the placebo group at the time of data cut‐off (24 weeks).<br/> <sup>3</sup>Data obtained from deaths in the intervention group at the time of data cut‐off (24 weeks).<br/> <sup>4</sup>See <a href="./references#CD010298-fig-0004" title="">Analysis 1.1</a>.<br/> <sup>5</sup><a href="./references#CD010298-bbs2-0001" title="MesaR , VerstovsekS , GuptaV , MascarenhasJ , AtallahE , SunW , et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib‐treated patients with myelofibrosis from COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733. MesaRA , GotlibJ , GuptaV , CatalanoJV , DeiningerMW , ShieldsAL , et al. Effect of ruxolitinib therapy on myelofibrosis‐related symptoms and other patient‐reported outcomes in COMFORT‐I: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology2013;31(10):1285‐92. [PUBMED: 23423753] MesaRA , KantarjianH , TefferiA , DueckA , LevyR , VaddiK , et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer2011;117(21):4869‐77. [PUBMED: 21480207] MesaRA , ShieldsA , HareT , Erickson‐ViitanenS , SunW , SarlisNJ , et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient‐reported outcomes in patients randomized to placebo in the COMFORT‐I study. Leukemia Research2013;37(8):911‐6. [PUBMED: 23684482] TalpazM , PaquetteR , AfrinL , HamburgS , JamiesonK , TerebeloH , et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176. VerstovsekS , KantarjianHM , EstrovZ , CortesJE , ThomasDA , KadiaT , et al. Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood2012;120(6):1202‐9. [PUBMED: 22718840 ] VerstovsekS , MesaR , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Long‐term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT‐I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800. VerstovsekS , MesaRA , GotlibJ , LevyR , GuptaV , DiPersioJF , et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo‐treated patients (COMFORT‐I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine2012;366(9):799‐807. [PUBMED: 22375971] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT‐I. Blood. 2011; Vol. 118: 278. VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DiPersioJF , et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology2013;161(4):508‐16. [PUBMED: 23480528] VerstovsekS , MesaRA , GotlibJ , LevyRS , GuptaV , DipersioJF , et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2‐year follow‐up of COMFORT‐I. Haematologica2013;98(12):1865‐71. [PUBMED: 24038026] VerstovsekS , MesaRA , GotlibJR , GuptaV , DiPersioJF , Catalano JV for the COMFORT‐I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)‐related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post‐Meeting Edition). 2012; Vol. 30(15 Suppl): 6624. VerstovsekS , MesaRA , GotlibJR , LevyRS , GuptaV , DiPersioJF , et al. Results of COMFORT‐I, a randomized double‐blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl). ">COMFORT‐I 2012</a> trial.<br/> <sup>6</sup>Downgraded one level due to limitations in the trial design or execution (high attrition bias).<br/> <sup>7</sup>Downgraded one level due to imprecision (low sample and number of events with an impact in the precision of the effect estimates). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ruxolitinib compared with placebo for treating myelofibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010298-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ruxolitinib compared with best available therapy for treating myelofibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Ruxolitinib compared to best available therapy for treating MF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with treating MF<br/> <b>Settings:</b> Ambulatory<br/> <b>Intervention:</b> Ruxolitinib<br/> <b>Comparison:</b> Best available therapy<sup>1</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Best available therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Ruxolitinib</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> <br/> (number of deaths at follow‐up (48 weeks<sup>2</sup>)) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> <br/> (11 to 130)<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.70</b> <br/> (0.20 to 2.47)<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression Free Survival</b> <br/> (number of patients who had progression at follow‐up (48 weeks<sup>2</sup>)) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> <br/> (132 to 342)<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.81</b> <br/> (0.47 to 1.39)<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety (AE, adverse drug reaction): anemia</b> <br/> Grades 3 or 4 according to National Cancer Institute<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>315 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>425 per 1000</b> <br/> (287 to 627) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.35</b> <br/> (0.91 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety (AE, adverse drug reaction): thrombocytopenia</b> <br/> Grades 3 or 4 according to National Cancer Institute<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 1000</b> <br/> (30 to 225) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> <br/> (0.44 to 3.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> <br/> European Organization for Research and Treatment of Cancer quality of life questionnaire core model. Scores ranges from 0 to 100. Scale from: 0 to 100.<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life in the intervention groups was<br/> <b>7.6 higher</b> <br/> (0.35 to 14.85 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in spleen size</b> <br/> Magnetic resonance imaging or computed tomography<br/> Follow‐up: 48 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 41.78</b> <br/> (2.61 to 669.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/> (1 trial<sup>1</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is provided in footnote #3. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR:</b> hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a>.<br/> <sup>2</sup><a href="./references#CD010298-bbs2-0002" title="CervantesF , KiladjianJJ , NiederwieserD , SirulnikA , StalbovskayaV , McQuityM , et al. Long‐term safety, efficacy, and survival findings from Comfort‐II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801. CervantesF , VannucchiAM , KiladjianJJ , Al‐AliHK , SirulnikA , StalbovskayaV , et al. Three‐year efficacy, safety, and survival findings from COMFORT‐II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood2013;122(25):4047‐53. [PUBMED: 24174625] GuglielmelliP , BiamonteF , RotunnoG , ArtusiV , ArtusoL , BernardisI , et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT‐II study. Blood2014;123(14):2157‐60. [PUBMED: 24458439] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine2012;366(9):787‐98. [PUBMED: 22375970] HarrisonC , KiladjianJJ , Al‐AliHK , GisslingerH , WaltzmanR , StalbovskayaV , et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF) or post‐essential thrombocythemia myelofibrosis (PET‐MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013). HarrisonCN , KiladjianJ , Al‐AliHK , GisslingerH , WaltzmanRJ , StalbovskayaV , et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post‐polycythemia vera‐myelofibrosis (PPV‐MF) or post‐essential thrombocythemia‐myelofibrosis (PET‐MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501. HarrisonCN , KiladjianJ‐J , Al‐AliHK , GisslingerH , KnoopsL , WaltzmanRJ , et al. Health‐related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795. HarrisonCN , KiladjianJ‐J , GisslingerH , NiederwieserD , PassamontiF , WaltzmanRJ , et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT‐II study. Blood. 2011; Vol. 118: 279. HarrisonCN , MesaRA , KiladjianJJ , Al‐AliHK , GisslingerH , KnoopsL , et al. Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology2013;162(2):229‐39. [PUBMED: 23672349] KiladjianJJ , GisslingerH , PassamontiF , NiederwieserD , MendelsonE , SirulnikLA , et al. Health‐related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT‐II study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JakelN , SirulnikA , et al. The use of erythropoietic‐stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post‐polycythemia vera myelofibrosis (PPV‐MF), and post‐essential thrombocythemia myelofibrosis (PET‐MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838. McMullinMF , HarrisonCN , NiederwieserD , DemuynckH , JäckelN , SirulnikA , et al. Anemia and the use of erythropoietic‐stimulating agents with ruxolitinib in the COMFORT‐II study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147. ">COMFORT‐II 2012</a> trial established the time of data cut‐off for its main outcome at 48 weeks.<br/> <sup>3</sup>Data obtained from deaths in the best available therapy group at the time of data cut‐off (48 weeks).<br/> <sup>4</sup>Data obtained from deaths in the intervention group at the time of data cut‐off (48 weeks).<br/> <sup>5</sup>See <a href="./references#CD010298-fig-0011" title="">Analysis 2.1</a>.<br/> <sup>6</sup>Downgraded one level due to limitations in the trial design or execution (open design).<br/> <sup>7</sup>Downgraded one level due to imprecision (low sample and number of events with an impact in the precision of the effect estimates).<br/> <sup>8</sup>See <a href="./references#CD010298-fig-0012" title="">Analysis 2.2</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ruxolitinib compared with best available therapy for treating myelofibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/full#CD010298-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010298-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ruxolitinib versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.27, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hematological adverse events (Adverse events observed in 10% or more of patients who received ruxolitinib. Harm (Grades 3 or 4). According to National Cancer Institute Common terminology criteria for adverse events) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Anemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [1.62, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.74 [2.32, 40.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.57 [1.02, 12.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Non‐hematological adverse events (Adverse events observed in 10% or more of patients who received ruxolitinib. Harm (Grades 3 or 4). According to National Cancer Institute common terminology criteria for adverse events) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.32, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.08, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Dyspnea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.07, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.31, 27.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 15.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Diarrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.87 [0.24, 100.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Pain in extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.87 [0.24, 100.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 15.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Health‐related quality of life: proportion of patients with a reduction of 50% or more in MFSAF scores at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.82 [4.40, 17.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Health‐related quality of life: Mean difference in MFSAF at follow‐up scores at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐87.90 [‐139.58, ‐36.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Reduction in spleen size (≥ 35%) (at 48 weeks follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>64.58 [9.08, 459.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Leukemia‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.52, 48.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ruxolitinib versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010298-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ruxolitinib versus best available therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.20, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival (at 48 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.47, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hematological adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Anemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.91, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [0.44, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐hematological adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.25, 6.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Dyspnea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Arthalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Diarrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.12, 51.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Pain in extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.52 [0.18, 67.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.12, 51.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.60 [0.35, 14.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Reduction in spleen size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At 24 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐31.90 [‐53.85, ‐9.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 At 48 weeks follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐37.4 [‐65.41, ‐9.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Reduction in spleen volume (≥ 35%) (at 24 and 48 weeks follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>41.78 [2.61, 669.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Leukemia‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.18, 2.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ruxolitinib versus best available therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010298.pub2/references#CD010298-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010298.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010298-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010298-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010298-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010298-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010298\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010298\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010298\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010298\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010298\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010298.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010298.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010298.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010298.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010298.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717923518"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010298.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717923522"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010298.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc3c6ed599377',t:'MTc0MDcxNzkyMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 